WO2011130729A2 - Methods for treating metabolic disorders using fgf - Google Patents
Methods for treating metabolic disorders using fgf Download PDFInfo
- Publication number
- WO2011130729A2 WO2011130729A2 PCT/US2011/032848 US2011032848W WO2011130729A2 WO 2011130729 A2 WO2011130729 A2 WO 2011130729A2 US 2011032848 W US2011032848 W US 2011032848W WO 2011130729 A2 WO2011130729 A2 WO 2011130729A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fgf
- compound
- mice
- metabolic disorder
- glucose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- Type 2 diabetes is a debilitating disease characterized by high- circulating blood glucose, insulin, and corticosteroid levels. The incidence of type 2 diabetes is high and rising and is becoming a leading cause of mortality, morbidity, and healthcare expenditure throughout the world (Amos et al., Diabetic Med. 14:Sl-85, 1997). Diabetes (and insulin resistant conditions) result in elevated levels of glucose in the blood. Prolonged high blood sugar may cause blood vessel and nerve damage.
- TZDs thiazolidinediones
- Actos ® pioglitazone
- TZDs reduce insulin resistance in adipose, muscle, and liver tissues (Oakes et al, Metabolism 46:935-942, (1997); Young et al.
- TZDs also lower the levels of free fatty acid (FFA) and triglycerides.
- TZDs administered alone or in combination with metformin have glucose-lowering effects in patients with type 2 diabetes and reduce plasma insulin concentrations (i.e., in hyperinsulinaemia) (Aronoff et al., Diabetes Care 2000; 23: 1605-1611; Lebovitz et al., J Clin Endocrinol Metab 2001; 86: 280-288; Phillips et al. Diabetes Care 2001; 24: 308-315).
- Abnormalities in lipid levels can also be treated (Day, Diabet Med 1999; 16: 179-192;
- compositions and methods for treating a metabolic disorder in an individual using an FGF-1 compound provides pharmaceutical compositions for treating a metabolic disorder comprising an FGF-1 compound.
- the FGF-1 compound is a functional fragment of FGF-1 (e.g., amino acids 1-140, 1-141, 14-135, etc.).
- the FGF-1 compound is a functional analog of FGF-1.
- the FGF-1 compound is a functional variant of FGF-1.
- the FGF-1 compound is an expression vector comprising a sequence encoding the FGF-1 compound.
- the pharmaceutical composition is formulated for intravenous administration. In some embodiments, the pharmaceutical composition is formulated for subcutaneous or intraperitoneal administration. In some embodiments, the pharmaceutical composition is formulated for a dose of the FGF-1 compound equivalent to 0.01- 1 mg FGF-1 per kg body weight of the individual, e.g., equivalent to 0.05-0.1, 0.1-0.2, 0.1-0.4, 0.05, 0.1, 0.2, 0.3, 0.4. 0.5 or higher mg FGF-1 per kg body weight. In some embodiments, the composition includes a second therapeutic agent, e.g., a TZD.
- a second therapeutic agent e.g., a TZD.
- the metabolic disorder is selected from the group consisting of elevated blood glucose (e.g., reduced ability to normalize glucose), impaired glucose tolerance, insulin resistance, type II diabetes, obesity, elevated percent body fat, and fatty liver (hepatic steatosis).
- the metabolic disorder is obesity.
- the individual has a BMI of 25 or higher, e.g., 26, 28, 30 or greater than 30.
- the metabolic disorder is hepatic steatosis.
- the metabolic disorder is insulin resistance.
- the metabolic disorder is impaired glucose tolerance.
- the invention provides methods of making a medicament for use in treating a metabolic disorder comprising an FGF-1 compound as described herein. Further provided is use of an FGF-1 compound for treating a metabolic disorder in an individual.
- Also provided are methods of treating a metabolic disorder in an individual comprising administering an FGF-1 compound to the individual, thereby treating the metabolic disorder.
- the metabolic disorder can be selected from the group consisting of elevated blood glucose (e.g. , reduced ability to normalize glucose), impaired glucose tolerance, insulin resistance, type II diabetes, obesity, elevated percent body fat, and fatty liver (hepatic steatosis).
- the metabolic disorder is obesity.
- the individual has a BMI of 25 or higher, e.g., 26, 28, 30 or greater than 30.
- the metabolic disorder is hepatic steatosis.
- the metabolic disorder is insulin resistance.
- the metabolic disorder is impaired glucose tolerance.
- the FGF-1 compound is a functional fragment of FGF-l(e.g., amino acids 1-140, 1-141, 14-135, etc.). In some embodiments, the FGF-1 compound is a functional analog of FGF-1. In some embodiments, the FGF-1 compound is a functional variant of FGF-1. In some embodiments, the FGF-1 compound is an expression vector comprising a sequence encoding the FGF-1 compound.
- the administering is intravenous. In some embodiments, the administering is subcutaneous or intraperitoneal. In some embodiments, the dose of the FGF- 1 compound administered is equivalent to 0.01- 1 mg FGF-1 per kg body weight of the individual, e.g., equivalent to 0.05-0.1, 0.1-0.2, 0.1-0.4, 0.05, 0.1, 0.2, 0.3, 0.4. 0.5 or higher mg FGF-1 per kg body weight. In some embodiments, the FGF-1 compound is administered once per day or less, e.g., every second day, every third day, every week, every other week, or less.
- the method further comprises administering a second therapeutic agent to the individual.
- the second therapeutic agent is administered at the same time ⁇ e.g., in the same composition) as the FGF-1 compound.
- the second therapeutic agent is administered at a different time than the FGF-1 compound.
- the second therapeutic agent is another treatment for a metabolic disorder ⁇ e.g., a TZD).
- the second therapeutic agent targets an associated symptom, e.g., pain or high blood pressure.
- the method comprises administering an effective amount of an FGF-1 inhibitor to the food animal.
- the FGF-1 inhibitor is an antisense compound specific for FGF-1, e.g., an expression vector comprising a sequence encoding the antisense compound.
- the FGF-1 inhibitor is an antibody ⁇ e.g., Shi et al. (2011) IUBMB Life 63: 129).
- the FGF-1 inhibitor is an inhibitor of the FGF-1 signaling pathway, e.g., a MAP kinase pathway inhibitor such as PD-098059, PD-161570, PD-173074, SU5402, or SB203580.
- the FGF-1 inhibitor is administered more than once, e.g., once/day, or with food. In some embodiments, the FGF-1 inhibitor is administered in combination with a high fat diet. In some embodiments, the method comprises generating an FGF-1 knockout or genetically altered FGF-1 inactive food animal, and feeding the animal with a high fat diet.
- FIG. 1 FGF-1 gene structure and expression.
- A The expression of the FGF-1 gene is directed by three distinct promoters driving the untranslated exons: 1 A, IB, and ID (open bars), spaced up to 70 kb apart. Alternative splicing of these untranslated exons to the three coding exons (closed bars) of the FGF-1 gene results in identical but differentially expressed FGF-1 polypeptides. This organization as shown for human and mouse is evolutionary conserved. Tissue distribution mRNA in mice for (B) FGF-1 A, (C) FGF-IB, and (D) FGF-ID.
- FGF-IA is a direct transcriptional target of PPARy. Determination of NR-mediated transcriptional regulation of (A) FGF-IA, (B) FGF-IB, and (C) FGF-ID using luciferase reporter assays.
- D conserveed PPAR response element (PPRE) within the proximal promoter of FGF-IA relative to the transcription start site (TSS). The sequences are shown from the indicated species, numbered SEQ ID NOs: 1-9 from top to bottom.
- E Alignment of the PPRE within the FGF-IA promoter of different species. Underline indicates nucleotide variations between the PPREs relative to human.
- F Species-specific response of the FGF-IA promoter to PPARy using luciferase reporter assays.
- FIG. 3 Transcriptional regulation of FGF-IA in vivo.
- Levels of FGF-IA (A, D) and FGF21 (B, C, E, F) mRNA in WAT and liver of wild-type mice (n 5).
- A, B, and C Fed or overnight fast, with or without rosiglitazone (5 mg/kg for 3 days p.o.).
- D, E, and F Fed, 2 weeks HFD, or overnight fast.
- FIG. 1 HFD-induced insulin resistance in FGF-1 KO mice.
- FGF-1 KO mice display (D) normal glucose tolerance when fed with control diet, but develop HFD-induced insulin resistance as indicated by (E) decreased glucose tolerance and (F) increased insulin tolerance after 6 mo HFD.
- G histology (H&E) of liver (upper panels) and WAT (lower panels) of wild-type (left panels) and FGF-1 KO (right panels) animals.
- FGF-1 KO mice display (H) normal pancreatic islet morphology and organization, (I) increased hepatic steatosis, and (J) normal adipocyte size and morphology.
- FIG. 1 FGF-1 and rosiglitazone stimulation of Glutl expression in 3T3-L1 adipocytes.
- A mRNA (top) and protein (bottom) levels of Glucose Transporter 1 (Glutl);
- FIG. 7 FGF-1 injection studies in rodents.
- A Fed blood glucose in ob/ob male mice treated with FGF-1 (0.5 mg/kg, s.c), rosiglitazone (TZD, 5 mg/kg, p.o.), or vehicle.
- FGF-1 was administered once daily, and blood glucose levels were measured at day 0 (basal levels before FGF-1 injection), day 3, and day 6, 1 hour after injection.
- the values ( ⁇ SE) shown are the average of the measurements of 5 animals in a group;
- B Sustained glucose lowering effects of FGF-1 : Fed blood glucose levels in ob/ob mice at indicated time points after the last FGF-1 injection at day 6.
- C-H 72 hrs after the sixth dose, another dose was given and effects of FGF-1 and TZD on (C) body weight, (D) total body fat, (E) lean weight, (F) weight gain, (G) liver weight, and (H) heart weight were determined.
- FIG. 9 Effect of FGF-1 (s.c, 0.5 mg/kg) on blood glucose levels of ob/ob mice.
- Figure 10 Effect of intravenous FGFl (0.2mg/kg) on blood glucose levels of ob/ob mice. IV administration of FGFl has acute glucose lowering effects, which last up to one week.
- FIG. 11 Effect of chronic FGF-1 on blood glucose. FGF-1 treatment every third day results in completely normalized blood glucose in ob/ob mice.
- FIG. 12 Effect of chronic FGFl on food intake.
- FGF-1 induces a reduced food intake during the first 1-2 weeks of chronic administration, but after two weeks food intake returned to normal.
- FIG. 13 Effect of chronic FGF-1 on body weight. FGF-1 treatment resulted in a reduced weight gain during the first week of chronic FGFl administration. After one week, weight gain is similar between control and FGFl -treated mice. This reduced weight gain corresponds with reduced food intake, but is more durable. Reduced weight gain is evident after food intake returns to normal.
- FIG. 14 Effect of chronic FGF-1 on total percent body fat. FGF-1 treated mice display reduced increase in percent body fat.
- Figure 15 Effect of chronic FGF-1 on percent lean mass. FGF-1 treated mice display increased lean mass as compared with control mice, further indicating that the reduced weight is due to a decrease in the percent body fat.
- Figure 16. Effect of chronic FGF-1 on glucose tolerance. Untreated mice show impaired glucose tolerance. After 4 weeks of FGF-1 administration, ob/ob mice display a more rapid and effective capacity to clear glucose from the blood, indicating that FGF-1 enhances glucose tolerance.
- Figure 17. Effect of chronic FGF-1 on insulin tolerance. After 4 weeks of chronic FGF-1 administration, ob/ob mice display increased insulin sensitivity. FGF-1 treated mice clear glucose from the blood more effectively than untreated mice.
- Figure 18 Effect of chronic FGF-1 on serum lipids. Serum levels of
- triglycerides, free fatty acids, and cholesterol are similar between control and FGF-1 treated mice.
- FIG. 19 Effect of chronic FGF-1 on hepatic steatosis. H&E staining of liver of A) control and B) FGFl -treated ob/ob mice. Control mice show mixed micro and macro vesicular steatosis with some periportal sparing. Steatosis affects most hepatocyes (>70%). There is little if any inflammatory infiltrate in either the portal tracts or lobules, which is typical liver histology for an ob/ob mouse. In contrast, livers from FGF-1 treated mice display clearing of fat in a periportal to mid zonal distribution. Steatosis is dramatically reduced compared to control and is mainly microvesicular. There is very little
- FIG. 20 Effect of chronic FGF-1 on hepatic glycogen.
- FGF-1 treated ice display increased levels of hepatic glycogen as compared to control mice.
- FIG. 21 PPARy binds to the FGF-1 promoter region in mature adipocytes.
- Chromatin was prepared from differentiated 3T3-L1 adipocytes and chromatin
- Figure 22 Assessment of delivery method on FGF-1 blood glucose effects.
- Subcutaenous, intraperitoneal, and intravenous delivery of FGF-1 display similar efficacy in normalizing blood glucose levels of ob/ob diabetic mice.
- Figure 23 Assessment of delivery method on duration of FGF-1 activity.
- FIG. 24 FGF-1 effects in db/db mice. Single subcutaneous injection of FGF-1 (0.5 mg/kg) normalizes blood glucose in db/db leptin receptor mutant diabetic mice. The db/db model is considered to represent a less severe diabetes model than ob/ob. The results indicate that FGF-1 is effective for treatment of less severe metabolic disorders.
- Figure 25 FGF1 effects in DIO mice. Single subcutaneous injection of FGF1 (0.5 mg/kg) normalizes blood glucose in diet-induced obesity mice (C57BL/6). Again, the results indicate that FGF-1 is effective for treatment of metabolic disorders arising from a number of causes.
- FIG. 26 Human recombinant FGF-1 is effective in mice. Single subcutaneous injection of human FGF1 (0.5 mg/kg) normalizes blood glucose in ob/ob mice.
- FIG. 27 Comparison of FGF1, FGF2, FGF9, and FGF10 effects. Single subcutaneous injection of FGFs (0.5 mg/kg) in ob/ob mice. Only FGF1 has glucose normalizing effects.
- FGF-1 has rapid and long-lasting effects, including normalizing blood glucose, increasing insulin sensitivity, reducing percent body fat and overall body weight, increasing percent lean mass, and reducing fatty liver (hepatic steatosis).
- FGF-1 compound refers to FGF-1 or a variant thereof (FGF-1 fragment, FGF-1 portion, modified form of FGF-1, protein having substantial identity to FGF-1, FGF-1 analog, etc.) that retains at least one FGF-1 activity ⁇ e.g., at least 10%, 20% , 30%>, 40%>, 50%, 60%, 70%, 80% or higher percent activity compared to FGF-1).
- FGF-1 compounds include functional FGF-1 fragments, functional FGF-1 variants, and functional FGF-1 analogs.
- An example of an FGF-1 compound that is substantially identical to FGF-1 is a protein having at least 80%, 85%, 90%, 95%, 98%, 99%, or 100% amino acid identity to FGF-1.
- the FGF-1 compound comprises a polypeptide having, e.g., 95%), 98%o, 99%) or higher % identity to FGF-1, where the non-identities represent conservative substitutions or additions or deletions that do not substantially change the activity.
- FGF-1 (or acidic FGF) is a secreted protein that binds heparin ⁇ e.g., heparin sulfate) and FGF receptor family members 1 and 4.
- the human protein is 155 amino acids in length, and the sequence is publically available at SwissProt accession number P05230.1.
- FGF-1 refers to naturally-occurring, isolated, recombinant, or synthetically-produced proteins. FGF-1 also includes allelic variants and species homo logs.
- FGF-1 activities include binding heparin, FGFR1, and FGFR4, and increasing expression of GLUTl and/or GLUT4. FGF-1 activities also include (among others) reducing glucose levels, improving glucose tolerance, and increasing insulin sensitivity in a diabetic individual. Additional FGF-1 activities include reducing percent body fat, fatty liver disease, and increasing percent lean mass in an individual.
- a functional FGF-1 fragment is a protein having less than the full length sequence of FGF-1 but retaining at least 25, 50, or 80% activity of at least one FGF-1 activity ⁇ e.g., FGF-1 (14-135, 1-140, 13-135, 1-141, etc.).
- the functional FGF-1 fragment can have an amino acid sequence of any length up to the full length FGF polypeptide sequence, e.g., 50, 50-80, 50-100, 120-150, 100-150, or more than 100 amino acids.
- the functional FGF fragment is at least 80%, 85%, 90%, 95%, 98%, or 100% identical to FGF-1 over the covered portion of the full length sequence ⁇ e.g., over 50-150 amino acids).
- the functional FGF-1 fragment has greater than 90%>, e.g., 95%, 98%>, 99% or higher % identity to FGF-1 1-141. In some embodiments, the functional FGF-1 fragment has greater than 90%, e.g., 95%, 98%, 99% or higher % identity to FGF-1 1-141, where the non- identities represent conservative substitutions or additions or deletions that do not
- a functional FGF-1 analog is a modified or synthetic ⁇ e.g., peptidomimetic) form of FGF-1 that retains at least 25, 50, or 80% activity of at least one FGF-1 activity.
- FGF-1 analogs that retain heparin-binding activity are disclosed in WO2006/093814.
- the FGF-1 analog can include non-naturally occurring amino acids, or modified amino acids, e.g., that improve the stability (in storage or in vivo) or pharmacological properties (tissue profile, half- life, etc.) of the protein.
- the functional FGF-1 analog can also be a functional FGF-1 variant, e.g., having greater than 90%>, e.g., 95%, 98%>, 99% or higher % identity to FGF-1.
- the functional FGF-1 analog has at least 95%, 98%, 99% or higher % identity to FGF-1, where the non-identities represent conservative substitutions or additions or deletions that do not substantially change the activity.
- recombinant when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified.
- recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.
- nucleic acid refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form, and complements thereof.
- polynucleotide refers to a linear sequence of nucleotides.
- nucleotide typically refers to a single unit of a polynucleotide, i.e., a monomer. Nucleotides can be
- ribonucleotides examples include single and double stranded DNA, single and double stranded RNA (including siRNA), and hybrid molecules having mixtures of single and double stranded DNA and RNA.
- complementary refers to the ability of a nucleic acid in a polynucleotide to form a base pair with another nucleic acid in a second
- polynucleotide For example, the sequence A-G-T is complementary to the sequence T-C-A.
- Complementarity may be partial, in which only some of the nucleic acids match according to base pairing, or complete, where all the nucleic acids match according to base pairing.
- amino acid polymers are used interchangeably to denote an amino acid polymer or a set of two or more interacting or bound amino acid polymers.
- the terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non- naturally occurring amino acid polymer.
- amino acid refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids.
- Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, ⁇ - carboxyglutamate, and O-phosphoserine.
- Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g. , an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium.
- Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid.
- Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid.
- Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
- Constantly modified variants applies to both amino acid and nucleic acid sequences.
- conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e.g., naturally contiguous, sequences.
- a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine.
- nucleic acid variations are "silent variations,” which are one species of conservatively modified variations.
- amino acid sequences one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.
- amino acids are typically conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).
- nucleic acids in the context of two or more nucleic acids, or two or more polypeptides, refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides, or amino acids, that are the same (i.e., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%o, 97%), 98%), 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection. See e.g. , the NCBI web site at ncbi.nlm.nih.gov/BLAST. Such sequences are then said to be
- substantially identical This definition also refers to, or may be applied to, the compliment of a nucleotide test sequence.
- the definition also includes sequences that have deletions and/or additions, as well as those that have substitutions. Algorithms can account for gaps and the like. Identity generally exists over a region that is at least about 25 amino acids or nucleotides in length, or over a region that is 50-100 amino acids or nucleotides in length.
- metabolic disorder is used broadly herein to refer to the conditions, diseases, and disorders associated with insulin and/ or glucose dysregulation. Metabolic disorders include type 2 diabetes, insulin insensitivity, glucose intolerance, elevated blood glucose levels, obesity, high percent body fat, fatty liver, etc. One of skill will understand that metabolic disorders are associated with and can result in a wide range of other disorders, e.g., high blood pressure, heart disease, poor circulation, etc., which can be ameliorated by addressing the metabolic disorder according to the methods of the invention.
- Biopsy or "biological sample from a patient” as used herein refers to a sample obtained from a patient having, or suspected of having, a metabolic disorder.
- the biopsy is a blood sample, which can be separated into blood components (plasma, serum, white blood cells, red blood cells, platelets, etc.).
- the sample is a tissue biopsy, such as needle biopsy, fine needle biopsy, surgical biopsy, etc. Tissue samples can be obtained from adipose, muscle, liver, etc.
- a "biological sample” or “cellular sample” can be obtained from a patient, e.g., a biopsy, from an animal, such as an animal model, or from cultured cells, e.g., a cell line or cells removed from a patient and grown in culture for observation.
- Biological samples include tissues and bodily fluids, e.g., blood, blood fractions, lymph, saliva, urine, feces, etc.
- Subject “Subject,” “patient,” “individual” and like terms are used interchangeably and refer to, except where indicated, mammals such as humans and non-human primates, as well as livestock and companion animals.
- the term does not necessarily indicate that the subject has been diagnosed with a metabolic disorder, but typically refers to an individual under medical supervision.
- a patient can be an individual that is seeking treatment, monitoring, adjustment or modification of an existing therapeutic regimen, etc.
- the terms can refer to an individual that has been diagnosed, is currently following a therapeutic regimen, or is at risk of developing a metabolic disorder, e.g., due to family history, sedentary lifestyle, etc.
- a "control" condition or sample refers to a sample that serves as a reference, usually a known reference, for comparison to a test condition or sample.
- a test sample can represent a patient sample, while a control can represent a sample from an individual known to have a metabolic disorder, or from an individual that is known to not have the disorder.
- a test sample can be taken from a test condition, e.g. , in the presence of a test compound, and compared to samples from known conditions, e.g., in the absence of the test compound (negative control), or in the presence of a known compound (positive control).
- a control can also represent an average value gathered from a number of tests or results.
- controls can be designed for assessment of any number of parameters.
- a control can be devised to compare therapeutic benefit based on pharmacological data (e.g., half-life) or therapeutic measures (e.g., comparison of benefit and/or side effects).
- pharmacological data e.g., half-life
- therapeutic measures e.g., comparison of benefit and/or side effects.
- controls are valuable in a given situation and be able to analyze data based on comparisons to control values. Controls are also valuable for determining the significance of data. For example, if values for a given parameter are widely variant in controls, variation in test samples will not be considered as significant.
- the terms "therapy,” “treatment,” and “amelioration” refer to any reduction in the severity of symptoms.
- the terms can refer to reducing blood glucose, increasing insulin sensitivity, reducing body weight, reducing percent body fat, increasing percent lean mass, reducing side effects of associated therapies, etc.
- the terms “treat” and “prevent” are not intended to be absolute terms.
- Treatment can refer to any delay in onset, amelioration of symptoms, improvement in patient survival, increase in survival time or rate, etc.
- the effect of treatment can be compared to an individual or pool of individuals not receiving the treatment, or to the same patient prior to treatment or at a different time during treatment.
- the severity of disease is reduced by at least 10%, as compared, e.g., to the individual before administration or to a control individual not undergoing treatment.
- the severity of disease is reduced by at least 25%, 50%>, 75%, 80%, or 90%, or in some cases, no longer detectable using standard diagnostic techniques.
- a therapeutically effective amount refers to that amount of the therapeutic agent sufficient to ameliorate a disorder, as described above.
- a therapeutically effective amount will show an increase or decrease of therapeutic effect at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%.
- Therapeutic efficacy can also be expressed as "-fold” increase or decrease.
- a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control.
- the effective amount of an FGF-1 compound can vary depending on co-administration of other therapeutics or metabolic profile of the individual (among other factors such as age, severity of disease, etc.).
- prognosis refers to a relative probability a subject has a given metabolic disorder. Symptoms and diagnostic criteria are summarized below. Similarly, the term “prognosis” refers to a relative probability that a certain future outcome may occur in the subject. For example, in the context of the present invention, prognosis can refer to the likelihood that an individual will develop a metabolic disorder. Prognosis can also refer to the likely severity of the disease (e.g., severity of symptoms, rate of functional decline, survival, etc.). The terms are not intended to be absolute, as will be appreciated by any one of skill in the field of medical diagnostics.
- FGF Fibroblast Growth Factor
- Fibroblast growth factors are a family of distinct polypeptide hormones that are widely expressed in developing and adult tissues (Baird et al., Cancer Cells, 3:239-243, 1991). FGFs play crucial roles in multiple physiological functions including angiogenesis, development, mitogenesis, pattern formation, cellular proliferation, cellular differentiation, metabolic regulation, and repair of tissue injury (McKeehan et al, Prog. Nucleic Acid Res. Mol. Biol. 59: 135-176, 1998; Beenken and Mohammadi, 2009). The FGF family now consists of at least twenty-three members, FGF-1 to FGF-23 (Reuss et al, Cell Tissue Res. 313: 139-157 (2003).
- FGFs bind to FGF receptors (FGFRs), of which there are four (FGFRl -4).
- the receptor binding specificity of each FGF is distinct, and can also depend on the particular isoform of the FGFR.
- FGFRl has at least 3 isoforms that result in different splice variants in the third Ig-like domain (Lui et al. (2007) Cancer Res. 67:2712).
- FGF signaling is also determined by the tissue specificity of the receptor and receptor isoform.
- FGF-1 can bind to all FGFRs, but is reported to be internalized only upon binding to FGFRl and FGFR4.
- FGF-1 compounds that can be used in the methods of the invention include full length human FGF-1, species homo logs thereof, and functional fragments thereof. Additional FGF-1 compounds that can be used include modified versions of FGF-1 (e.g., modified to increase stability, e.g., PEGylated or including non-naturally occurring amino acids), functional analogs of FGF-1, and functional FGF-1 variants with substantial identity to FGF-1.
- FGF-1 compounds include those that retain at least one FGF-1 activity, e.g., binding heparin, FGFR1, and FGFR4, and increasing expression of GLUT1 and/or GLUT4.
- FGF-1 acitivities include (among others) reducing (normalizing) glucose levels, improving glucose tolerance, and increasing insulin sensitivity in a diabetic individual.
- Additional FGF-1 activities include reducing percent body fat, fatty liver disease, and increasing percent lean mass in an individual.
- the FGF-1 compound is a functional FGF-1 variant, functional FGF-1 fragment, and/or functional FGF-1 analog. That is, the FGF-1 compound can be a functional FGF-1 fragment with variations and modified or non-naturally occurring amino acids, as long as the FGF-1 compound retains at least one FGF-1 activity.
- the FGF-1 compound is substantially identical to full length FGF-1 or a fragment thereof, e.g., at least 95, 98, or 99% identical over the relevant length of FGF-1, where the non-identities include conservative substitutions or deletions or additions that do not affect the FGF-1 activity.
- FGF-1 amino acids that are involved in FGF-1 activities, and thus less amenable to substitution or deletion, include Tyr-15, Arg-35, Asn-92, Tyr-94, Lys-101, His-102, Trp-107, Leu-133, and Leu-135. Also included are Lys-112, Lys- 113, Lys-118, Arg-122, and Lys-128, which are involved in heparin interactions. The position of these residues is with reference to the 155 amino acid human sequence, but can be determined for species homologs. [0072] In some embodiments, the FGF-1 compound comprises amino acids 1-140 of FGF- 1, or a sequence having at least 90% identity to amino acids 1-140 of FGF-1 that retains at least one FGF-1 activity.
- the FGF-1 activity is normalizing blood glucose levels in an individual. In some embodiments, the FGF-1 activity is reducing percent body fat in an individual. In some embodiments, the FGF-1 activity is increasing insulin sensitivity in an individual. In some embodiments, the FGF-1 activity is binding to FGFR1 or FGFR4. In some embodiments, the FGF-1 activity is increasing expression of GLUT1.
- the FGF-1 compound may be generated, isolated, and/or purified by any means known in the art.
- standard recombinant methods see Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY (1989); Deutscher, Methods in Enzymology 182: 83-9 (1990); Scopes, Protein Purification:
- the FGF-1 compound can be modified, e.g., to improve stability or its
- Chemical modifications include, e.g., adding chemical moieties, creating new bonds, and removing chemical moieties.
- Modifications at amino acid side groups include acylation of lysine ⁇ -amino groups, N-alkylation of arginine, histidine, or lysine, alkylation of glutamic or aspartic carboxylic acid groups, and deamidation of glutamine or asparagine.
- Modifications of the terminal amino group include the des-amino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications.
- Modifications of the terminal carboxy group include the amide, lower alkyl amide, dialkyl amide, and lower alkyl ester modifications.
- Examples of compounds that can improve the pharmacological profile of the FGF-1 compound include water soluble polymers, such as PEG, PEG derivatives, polyalkylene glycol (PAG), polysialyic acid, hydroxyethyl starch, peptides ⁇ e.g., Tat (from HIV), Ant (from the Drosophila antennapedia homeotic protein), or poly-Arg), and small molecules ⁇ e.g., lipophilic compounds such as cholesterol or DAG).
- water soluble polymers such as PEG, PEG derivatives, polyalkylene glycol (PAG), polysialyic acid, hydroxyethyl starch, peptides ⁇ e.g., Tat (from HIV), Ant (from the Drosophila antennapedia homeotic protein), or poly-Arg), and small molecules ⁇ e.g., lipophilic compounds such as cholesterol or DAG).
- the FGF-1 is linked to a heparin molecule, which can improve the stability of FGF-1, and prevent interaction with heparin in vivo. Linking heparin to FGF-1 ensures that more of the modified FGF-1 remains in circulation than it would without the heparin modification.
- the FGF-1 compound can be expressed recombinantly using routine techniques in the field of recombinant genetics. Standard techniques are used for cloning, DNA and RNA isolation, amplification and purification. Generally enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like are performed according to the manufacturer's specifications. Basic texts disclosing the general methods of use in this invention include Sambrook and Russell eds. (2001) Molecular Cloning: A Laboratory Manual, 3rd edition; the series Ausubel et al. eds. (2007 with updated through 2010) Current Protocols in Molecular Biology, among others known in the art.
- nucleic acid sequence such as the nucleic acid sequences encoding an FGF-1 compound
- the expression vector typically contains a strong promoter or a promoter/enhancer to direct transcription, a transcription/translation terminator, and for a nucleic acid encoding a protein, a ribosome binding site for translational initiation.
- the promoter is operably linked to the nucleic acid sequence encoding a polypeptide of the invention or a subsequence thereof.
- the particular expression vector used to transport the genetic information into the cell is not particularly critical. Any of the conventional vectors used for expression in eukaryotic or prokaryotic cells may be used. Standard bacterial expression vectors include plasmids such as pBR322 based plasmids, pSKF, pET23D, and fusion expression systems such as GST and LacZ. Epitope tags can also be added to the recombinant polypeptides to provide convenient methods of isolation, e.g., His tags.
- enzymatic cleavage sequences ⁇ e.g., Met-(His)g-Ile-Glu-GLy-Arg which form the Factor Xa cleavage site
- Bacterial expression systems for expressing the polypeptides are available in, e.g., E. coli, Bacillus sp., and Salmonella (Palva et al, Gene 22:229-235 (1983); Mosbach et al, Nature 302:543-545 (1983). Kits for such expression systems are commercially available.
- Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available.
- Standard transfection methods can be used to produce cell lines that express large quantities of polypeptides of the invention, which are then purified using standard techniques (see, e.g., Colley et al., J. Biol. Chem., 264: 17619-17622 (1989); Guide to Protein
- Transformation of cells is performed according to standard techniques (see, e.g., Morrison, J. Bact., 132:349- 351 (1977); Clark-Curtiss & Curtiss, Methods in Enzymology, 101 :347-362 (Wu et al, eds, 1983).
- any of the well known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, liposomes, microinjection, plasma vectors, and viral vectors (see, e.g., Sambrook et al, supra).
- FGF-1 can be purified to substantial purity by standard techniques known in the art, including, for example, extraction and purification from inclusion bodies, size differential filtration, solubility fractionation ⁇ i.e., selective precipitation with such substances as ammonium sulfate); column chromatography, immunopurification methods, etc.
- the FGF-1 compound can also be chemically synthesized using known methods including, e.g., solid phase synthesis ⁇ see, e.g., Merrifield, J. Am. Chem. Soc, 85:2149-2154 (1963) and Abelson et al, Methods in Enzymology, Volume 289: Solid-Phase Peptide Synthesis (1st ed. 1997)). Polypeptide synthesis can be performed using manual techniques or by automation. Automated synthesis can be achieved, for example, using Applied
- polypeptide Synthesizer Perkin Elmer
- various fragments of the polypeptide (and any modified amino acids) can be chemically synthesized separately and then combined using chemical methods to produce the full length polypeptide.
- the sequence and mass of the polypeptides can be verified by GC mass spectroscopy.
- the polypeptides can be modified, for example, by N-terminal acetyl- and C-terminal amide- groups as described above. Synthesized polypeptides can be further isolated by HPLC to a purity of at least about 80%, preferably 90%, and more preferably 95%>.
- the invention further provides methods of inhibiting FGF-1 to induce fatty liver in a food animal, e.g., a bird such as a duck, goose, quail, etc.
- the inhibited expression or activity can be 40%, 50%, 60%, 70%, 80%, 90% or less than that in a untreated or wild type control. In certain instances, the inhibition is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more in comparison to a control.
- inhibition of FGF-1 is accompanied by a high fat diet.
- the method comprises generating a genetically modified animal with defective FGF-1 activity ⁇ e.g., an FGF-1 knockout animal).
- FGF-1 is inhibited by
- an FGF-1 inhibitor to the animal.
- the inhibitor is administered more than once, e.g., on a regular schedule (daily, weekly, etc.) or with food.
- the FGF-1 inhibitor can be an antisense compound.
- antisense is used herein as a general term referring to R A targeting strategies for reducing gene expression.
- Antisense includes R Ai, siRNA, shRNA, etc.
- the antisense sequence is identical to the targeted sequence (or a fragment thereof), but this is not necessary for effective reduction of expression.
- the antisense sequence can have 85, 90, 95, 98, or 99% identity to the complement of a target RNA or fragment thereof.
- the targeted fragment can be about 10, 20, 30, 40, 50, 10-50, 20-40, 20-100, 40-200 or more nucleotides in length.
- RNAi refers to RNA interference strategies of reducing expression of a targeted gene.
- RNAi technique employs genetic constructs within which sense and anti-sense sequences are placed in regions flanking an intron sequence in proper splicing orientation with donor and acceptor splicing sites. Alternatively, spacer sequences of various lengths can be employed to separate self-complementary regions of sequence in the construct.
- intron sequences are spliced-out, allowing sense and anti-sense sequences, as well as splice junction sequences, to bind forming double- stranded RNA.
- RNA interference is described and discussed in Bass, Nature 411 : 428-29 (2001); Elbahir et al, Nature 411 : 494-98 (2001); and Fire et al, Nature 391 : 806-11 (1998); and WO 01/75164, where methods of making interfering RNA also are discussed.
- siRNA refers to small interfering RNAs, that are capable of causing interference with gene expression and can cause post-transcriptional silencing of specific genes in cells, for example, mammalian cells (including human cells) and in the body, for example, in a mammal (including humans).
- the siRNAs based upon the sequences and nucleic acids encoding the gene products disclosed herein typically have fewer than 100 base pairs and can be, e.g., about 30 bps or shorter, and can be made by approaches known in the art, including the use of complementary DNA strands or synthetic approaches.
- the siRNAs are capable of causing interference and can cause post-transcriptional silencing of specific genes in cells, for example, mammalian cells (including human cells) and in the body, for example, in a mammal (including humans).
- Exemplary siRNAs have up to 40bps, 35bps, 29 bps, 25 bps, 22 bps, 21 bps, 20 bps, 15 bps, 10 bps, 5 bps or any integer thereabout or therebetween.
- Tools for designing optimal inhibitory siRNAs include that available from DNAengine Inc. (Seattle, WA) and Ambion, Inc. (Austin, TX).
- a "short hairpin RNA” or “small hairpin RNA” is a ribonucleotide sequence forming a hairpin turn which can be used to silence gene expression. After processing by cellular factors the short hairpin RNA interacts with a complementary RNA thereby interfering with the expression of the complementary RNA.
- the FGF-1 inhibitor can also be an antibody that interferes with FGF-1 signaling, e.g., a FGF-1 specific antibody, or a functional fragment thereof.
- FGF-1 signaling e.g., a FGF-1 specific antibody, or a functional fragment thereof.
- An example of an FGF-1 antibody is described, e.g., in Shi et al. (2011) IUBMB Life 63: 129, but several are commercially available.
- Antibodies can exist as intact immunoglobulins or as any of a number of well-characterized fragments that include specific antigen-binding activity.
- the "variable region" of the antibody contains the antigen-binding activity, and is most critical in specificity and affinity of binding. See Paul, Fundamental Immunology (2003). Such fragments can be produced by digestion with various peptidases. Pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)' 2 , a dimer of Fab which itself is a light chain joined to V H -C H 1 by a disulfide bond. The F(ab)' 2 may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)' 2 dimer into an Fab' monomer.
- the Fab' monomer is essentially Fab with part of the hinge region (see Fundamental Immunology (Paul ed., 3d ed. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology.
- the term antibody includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g. , single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty et ah, Nature 348:552-554 (1990)).
- the FGF-1 inhibitor can also be an inhibitor of the FGF-1 signaling pathway, e.g., a MAP kinase pathway inhibitor such as PD-098059, PD-161570, SU5402, or SB203580.
- a MAP kinase pathway inhibitor such as PD-098059, PD-161570, SU5402, or SB203580.
- the FGF-1 compound described herein can be used to treat metabolic disorders, e.g., type 2 diabetes, insulin insensitivity, glucose intolerance, metabolic syndrome, fatty liver disease, obesity, and conditions related thereto. Related to the obesity application, the FGF-1 compound can also be used to reduce percentage body fat and/or increase the percentage of lean mass in an individual. Conditions related to the metabolic disorders, that can also benefit from treatment with and FGF-1 compound include high blood pressure
- cardiovascular disease hyperglycemia
- hyperuricemia hyperuricemia
- polycystic ovary syndrome hyperglycemia
- Metabolic syndrome also known as metabolic syndrome X or syndrome X
- a diagnosis of metabolic syndrome requires at least three of the following criteria (see International Diabetes Foundation (IDF) and U.S. National Cholesterol Education Program (NCEP)):
- Lowered HDL cholesterol ⁇ 40 mg/dL (males), ⁇ 50 mg/dL (females)
- Raised blood pressure (BP) hypertension: systolic BP > 130 or diastolic BP >85 mm Hg
- Elevated LDL cholesterol is marked by levels above about 100, about 130, about 160 or about 200 mg/dL. Metabolic syndrome may also be related to elevated total cholesterol.
- Impaired glucose intolerance is defined as a two-hour glucose levels (glycemia) of about 140 to about 199 mg/dL (7.8 to 11.0 mmol) on the 75 -g oral glucose tolerance test (according to WHO and ADA). Glycemia of about 200 mg/dl or greater is considered diabetes mellitus.
- Hyperglycemia, or high blood sugar can be defined as a blood glucose level higher than about 7, about 10, about 15, or about 20 mmol/L.
- Hypoglycemia or low blood sugar, can be defined as preprandial blood glucose below about 4 or about 6 mmol/L (72 to 108 mg/dl) or 2-hour postprandial blood glucose below about 5 or about 8 mmol/L (90 to 144 mg/dl).
- Insulin resistance is defined as a state in which a normal amount of insulin produces a subnormal biologic response. Insulin resistance can be measured by the hyperinsulinemic euglycemic clamp technique, Homeostatic Model Assessment (HOMA), or Quantitative insulin sensitivity check index (QUICKI).
- Hyperuricemia is an abnormally high level of uric acid in the blood, e.g., above 360 ⁇ /L (6 mg/dL) for women and 400 ⁇ /L (6.8 mg/dL) for men.
- PCOS Polycystic ovarian syndrome
- Metabolic syndrome may also be associated with acanthosis nigricans.
- Metabolic syndrome may also be associated with a pro-inflammatory state (e.g., elevated C-reactive protein levels in the blood, e.g., above 10 mg/L) and microalbuminuria (urinary albumin excretion ratio > 20 mg/min or albumin: creatinine ratio > 30 mg/g).
- a pro-inflammatory state e.g., elevated C-reactive protein levels in the blood, e.g., above 10 mg/L
- microalbuminuria urinary albumin excretion ratio > 20 mg/min or albumin: creatinine ratio > 30 mg/g
- the FGF-1 compound can be used to treat fatty liver disease or a condition related thereto.
- the fatty liver disease can be a method of treating
- nonalcoholic steatohepatitis NASH
- nonalcoholic fatty liver disease NAFLD
- simple fatty liver steatosis
- cirrhosis hepatitis, liver fibrosis, or steatonecrosis.
- Fatty liver disease can be assessed by diagnostic methods known in the art including liver enzyme tests (ALT, AST), liver ultrasound, FibroTest®, SteatoTest®, coagulation studies including international normalized ratio (INR), as well as blood tests including M30-Apoptosense ELISA, erythrocyte sedimentation rate, glucose, albumin, and renal function.
- Fatty liver disease may also be associated with a pro-inflammatory state (e.g., elevated C-reactive protein levels in the blood, e.g., above 10 mg/L) as well as hepatocellular carcinoma.
- Fatty liver disease may also be associated with abetalipoproteinemia, glycogen storage diseases, Weber-Christian disease, Wolman disease, acute fatty liver of pregnancy, lipodystrophy, inflammatory bowel disease, HIV, and hpatitis C (especially genotype 3), and alpha 1 -antitrypsin deficiency.
- the FGF-1 compound is used to reduce percentage body fat, increase percentage lean mass, or to treat obesity (as well as associated conditions).
- the method can be used to treat class I obesity, class II obesity, class III obesity, elevated body weight, elevated body mass index (BMI), elevated body volume index (BVI), elevated body fat percentage, elevated fat to muscle ratio, elevated waist circumference, or elevated waist- hip ratio.
- Class I obesity is characterized by a BMI of about 30 to about 35
- class II obesity severe obesity
- class III obesity morbid obesity
- a BMI of greater than about 45 or 50 is considered super obese.
- Elevated body weight can be assessed in consideration of age, gender, height, frame, and/or ethnicity.
- Elevated waist-hip ratio is defined as greater than about 0.9 for men and greater than about 0.7 for women.
- Metabolic disorders are inter-related and can result in disorders across various systems. Addressing the core metabolic disorder can reduce the severity of related conditions in a patient, including, e.g. : cardiovascular disorders including, e.g., ischemic heart disease, angina and myocardial infarction, congestive heart failure, high blood pressure, abnormal cholesterol levels, deep vein thrombosis, and pulmonary embolism,
- cardiovascular disorders including, e.g., ischemic heart disease, angina and myocardial infarction, congestive heart failure, high blood pressure, abnormal cholesterol levels, deep vein thrombosis, and pulmonary embolism
- neurological disorders including, e.g., stroke, meralgia paresthetica, migraines, idiopathic, and intracranial hypertension,
- rheumatological and orthopedic disorders including, e.g., gout, poor mobility, osteoarthritis, and lower back pain,
- dermato logical disorders including, e.g., stretch marks, acanthosis nigricans, lymphedema, cellulitis,
- gastroesophageal reflux disease GEF
- cholelithiasis gallstones
- respiratory disorders including, e.g. , obstructive sleep apnea, obesity hypoventilation syndrome, asthma, and increased complications during general anaesthesia, urology and nephrology disorders including, e.g., erectile dysfunction, urinary incontinence, chronic renal failure, and hypogonadism.
- the FGF-1 compounds can be used and formulated into any of a number of pharmaceutical compositions, including those described in the United States Pharmacopeia (U.S. P.), Goodman and Gilman 's The Pharmacological Basis of Therapeutics, 10 th Ed., McGraw Hill, 2001; Katzung, Ed., Basic and Clinical Pharmacology, McGraw- Hill/ Appleton & Lange, 8 th ed., September 21, 2000; Physician 's Desk Reference (Thomson Publishing; and/or The Merck Manual of Diagnosis and Therapy, 18 th ed., 2006, Beers and Berkow, Eds., Merck Publishing Group; or, in the case of animals, The Merck Veterinary Manual, 9 th ed., Kahn Ed., Merck Publishing Group, 2005.
- compositions disclosed herein can be administered by any means known in the art.
- compositions may include administration to a subject intravenously, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostaticaly, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, intramuscularly, intrathecally, subcutaneously, subconjunctival, intravesicularlly, mucosally, intrapericardially, intraumbilically,
- Administration can be local, e.g., to adipose tissue or to the liver, or systemic.
- Solutions of the active compounds as free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations can contain a preservative to prevent the growth of microorganisms.
- aqueous solutions for parenteral administration in an aqueous solution, for example, the solution should be suitably buffered and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- Aqueous solutions in particular, sterile aqueous media, are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
- one dosage can be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion.
- Sterile injectable solutions can be prepared by incorporating the active compounds or constructs in the required amount in the appropriate solvent followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium.
- Vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredients, can be used to prepare sterile powders for
- DMSO can be used as solvent for extremely rapid penetration, delivering high concentrations of the active agents to a small area.
- Heparin can interfere with FGF-1 circulation when the FGF-1 compound is not administered intravenously.
- the FGF-1 compound can be linked to a heparin molecule, or another compound that interferes with FGF-1 binding to heparin.
- the FGF-1 -heparin interaction in vivo reduces the amount of circulating FGF-1, and the duration of the therapeutic effect.
- the invention provides a pharmaceutical composition comprising an FGF-1 compound linked to heparin. Diabetes medications are commonly administered s.c, thus, it can be more convenient to the patient to receive the FGF-1 compound in the same s.c.
- compositions can be delivered via intranasal or inhalable solutions or sprays, aerosols or inhalants.
- Nasal solutions can be aqueous solutions designed to be administered to the nasal passages in drops or sprays.
- Nasal solutions can be prepared so that they are similar in many respects to nasal secretions.
- the aqueous nasal solutions usually are isotonic and slightly buffered to maintain a pH of 5.5 to 6.5.
- antimicrobial preservatives similar to those used in ophthalmic preparations, and appropriate drug stabilizers, if required, may be included in the formulation.
- Oral formulations can include excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders.
- oral pharmaceutical compositions will comprise an inert diluent or assimilable edible carrier, or they may be enclosed in hard or soft shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
- the active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
- Such compositions and preparations should contain at least 0.1% of active compound.
- the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 75% of the weight of the unit, or preferably between 25-60%>.
- the amount of active compounds in such compositions is such that a suitable dosage can be obtained.
- FGF-1 is administered using a gene therapy construct, e.g., as described in Nikol et al. (2008) Mol Ther.
- a gene therapy construct e.g., as described in Nikol et al. (2008) Mol Ther.
- an individual is treated for a metabolic disorder by administering to the individual an expression vector comprising a sequence that codes for a FGF-1 compound.
- the methods of inducing fatty liver in an animal can rely on administration of an expression vector, in this case, an expression vector encoding an antisense construct specific for FGF-1.
- a polynucleotide encoding FGF-1 is introduced into a cell in vitro and the cell is subsequently introduced into a subject.
- the cells are first isolated from the subject and then re -introduced into the subject after the polynucleotide is introduced.
- FGF-1 -encoding polynucleotides or FGF-1 inhibitory polynucleotides are introduced directly into cells in the subject in vivo.
- Non-viral vector delivery systems include DNA plasmids, naked nucleic acid, and nucleic acid complexed with a delivery vehicle such as a liposome.
- Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell.
- Methods of non- viral delivery of nucleic acids encoding engineered polypeptides of the invention include lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection is described, e.g., in US 5,049,386, US 4,946,787; and US 4,897,355, and lipofection reagents are sold commercially ⁇ e.g.,
- Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides include those of Feigner, WO 91/17424, WO 91/16024. Delivery can be to cells ⁇ ex vivo administration) or target tissues (in vivo administration).
- the preparation of lipid:nucleic acid complexes, including targeted liposomes such as immuno lipid complexes, is well known to one of skill in the art ⁇ see, e.g., Crystal, Science 270:404-410 (1995); Blaese et al., Cancer Gene Ther. 2:291-297 (1995); Behr et al, Bioconjugate Chem.
- RNA or DNA viral based systems can be used to target the delivery of
- polynucleotides carried by the virus to specific cells in the body and deliver the
- Viral vectors can be administered directly to patients (in vivo) or they can be used to transfect cells in vitro. In some cases, the transfected cells are administered to patients ⁇ ex vivo).
- Conventional viral based systems for the delivery of polypeptides of the invention could include retroviral, lentivirus, adenoviral, adeno- associated and herpes simplex virus vectors for gene transfer.
- Viral vectors are currently the most efficient and versatile method of gene transfer in target cells and tissues. Integration in the host genome is possible with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, often resulting in long term expression of the inserted transgene, and high transduction efficiencies.
- the invention provides methods of treating, preventing, and/or ameliorating a metabolic disorder in a subject in need thereof.
- the course of treatment is best determined on an individual basis depending on the particular characteristics of the subject.
- the treatment can be administered to the subject on a daily, twice daily, every other day, bi-weekly, weekly, monthly or any applicable basis that is therapeutically effective.
- the treatment can be administered alone or in combination with at least one other therapeutic agent, e.g. , targeting the same metabolic disorder or a related symptom.
- the additional agent can be administered simultaneously with the FGF-1 compound, at a different time, or on an entirely different therapeutic schedule (e.g., the FGF-1 compound can be administered daily, while the additional agent is weekly).
- the dosage of a therapeutic agent administered to a patient will vary depending on a wide range of factors. For example, it would be necessary to provide substantially larger doses to humans than to smaller animals. The dosage will depend upon the size, age, sex, weight, medical history and condition of the patient, use of other therapies, the potency of the substance being administered, and the frequency of administration.
- the dose of the FGF-1 compound can be equivalent to 0.005- 1 mg FGF-1 per kg body weight.
- the dose can be equivalent to 0.01-0.1 , 0.1-0.2, 0.1-0.5. 0.2-0.5, 0.5-0.8. or 0.5 or more mg FGF-1 per kg body weight.
- One of skill will understand and be able to adjust to situations where the FGF-1 compound is smaller (e.g., a functional FGF-1 fragment) or larger (e.g., a modified FGF-1 polypeptide) than FGF-1.
- the total daily dosage can be divided and administered in portions during the day if desired.
- the pharmaceutical preparation can be packaged or prepared in unit dosage form.
- the preparation is subdivided into unit doses containing appropriate quantities of the active component, e.g. , according to the dose of the therapeutic agent.
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of
- the FGF-1 compound is co-administered with at least one additional therapeutic agent, e.g. , another therapeutic agent for treating a metabolic disorder, or a therapeutic agent to address associated symptoms, e.g., a blood thinner or analgesic.
- additional therapeutic agent e.g. , another therapeutic agent for treating a metabolic disorder, or a therapeutic agent to address associated symptoms, e.g., a blood thinner or analgesic.
- Therapeutic agents commonly used for metabolic disorders include drugs from the following classes: alpha-glucosidase inhibitors, amylin agonists, dipeptidyl-peptidase 4 (DPP-4) inhibitors, meglitinides, sulfonylureas and PPAR agonists such as thiazolidinediones (TZD).
- the PPAR agonist e.g., PPARy agonist, can include, e.g., aleglitazar, farglitazar,
- TZD muraglitazar, tesaglitazar, and thiazolidinedione
- exemplary TZDs include pioglitazone (Actos®), rosiglitazone (Avandia®), rivoglitazone, and troglitazone (Hauner, Diabetes Metab Res Rev 18:S10-S15 (2002)).
- Additional complementary active agents such as biguanides ⁇ e.g., metformin) or sulfonylureas, can also be used in appropriate circumstances.
- biguanides e.g., metformin
- sulfonylureas can also be used in appropriate circumstances.
- the combination of an FGF-1 compound with another therapeutic agent can result in a synergistic effect with enhanced efficacy in the treatment of metabolic disorders such as type 2 diabetes and related conditions.
- the synergy allows for reduced dosages of the active agents in combination as compared to the dosages for either active individually.
- the reduced dosage can help reduce any side effects that may appear.
- the effective amount of the additional (second) therapeutic agent and the effective amount of the FGF-1 compound are together effective to reduce the symptoms/ effects of metabolic disorder.
- the combination is an FGF-1 compound and TZD.
- the FGF/TZD combination allows for a reduced dose of TZD required for therapeutic treatment of type 2 diabetes, thereby
- the amount of TZD administered in combination with the FGF-1 compound is reduced by about 10%, 20%>, 30%, 40%, 50%, 60%, 70%, or to about 80% compared to the typical dose of TZD utilized in the treatment of type 2 diabetes.
- the amount of rosiglitazone can be about 4 mg to about 8 mg per day ⁇ e.g., about 2 mg, about 4 mg, or about 8 mg per dose).
- the amount of pioglitazone can be about 15 mg to about 45 mg per day, e.g., about 30 mg per day.
- Ob/ob male mice (8 wks old, B6.Cg-Lep ob Ldlr tmlHer /J) were from Jackson labs.
- the Ob/ob mouse model is an animal model for hyperglycemia, insulin resistance, and obesity.
- Male ob/ob mice are used to monitor plasma glucose levels, lipid levels, etc.
- 3T3-L1 mouse pre-adipocytes were from American Type Culture Collection (ATCC, Rockville, Md.). Cells were maintained at sub-confluence in growth medium (GM) containing 10% calf serum in Dulbecco's modified Eagle's medium (DMEM) at 37°C and 5%> C0 2 .
- GM growth medium
- DMEM Dulbecco's modified Eagle's medium
- For standard adipocyte differentiation cells were stimulated at 2 days post confluency (referred as day 0) with differentiation medium (DM) containing 10% fetal bovine serum (FBS), 5 ⁇ g/ml insulin, 1 ⁇ dexamethasone, and 0.5 ⁇ 3-isobutyl-l- methylxanthine (IBMX) for 48 hours.
- FBS fetal bovine serum
- IBMX 3-isobutyl-l- methylxanthine
- Western blotting was performed as described using polyclonal goat anti-human FGF-1 (C-19) antibody (1 :200, Santa Cruz), anti-AKT (1 : 1000, Cell Signaling Technology, 9272), monoclonal rabbit anti-GSK3b (1 : 1000, Cell Signaling Technology, 9315), and polyclonal rabbit anti-p44/42 MAPK (1 : 1000, Cell Signaling Technology, 9102).
- Antibody binding was detected using peroxidase-conjugated donkey anti-goat IgG (1 :5000, Santa Cruz).
- Serum analysis Blood was collected by tail bleeding either in the ad libitum fed state or following overnight fasting. Free fatty acids (Wako), triglycerides (Thermo), and cholesterol (Thermo) were measured using enzymatic colorimetric methods following the manufacturer's instructions. Serum insulin levels were measured using an Ultra Sensitive Insulin ELISA kit (Crystal Chem). Serum adiponectin levels were measured by ELISA (Millipore). Plasma adipokine levels were measured using a MilliplexTM MAP kit
- GTT Glucose tolerance tests
- Mice were injected intraperitoneally (i.p.) with 1 g of glucose per/kg body weight, and blood glucose was monitored at 0, 15, 30, 60, 90, and 120 min using a OneTouch Ultra glucometer (Lifescan Inc).
- Insulin tolerance tests (ITT) were conducted after overnight fasting. Mice were injected i.p. with 0.5 U of insulin/kg body weight (Humulin R; Eli Lilly), and blood glucose was monitored at 0, 15, 30, 60, 90, and 120 min using a OneTouch Ultra glucometer (Lifescan Inc).
- Example 5 Real-time metabolic analyses were conducted in an undisturbed room under 12 h/12 h light/dark cycles using a Comprehensive Lab Animal Monitoring System (Columbus Instruments).
- ob/ob male mice (8 wk old) were randomized into three groups and treated with daily subcutaneous (s.c.) injections of recombinant mouse FGF-1 (0.5 mg/kg in PBS), oral rosiglitazone (TZD, 5 mg/kg in 0.5% carboxymethyl cellulose), or vehicle. Blood glucose levels were measure in fed animals one hour after treatment. Total body composition analysis was performed using an EchoMRI-100TM (Echo Medical Systems, LLC).
- Example 1 Identification of FGF- 1 as a direct target of PPARy.
- Ontology which encompasses a validated cDNA expression library including all 49 mouse NHRs combinatorially paired with a large collection of pathway specific promoter- reporter libraries.
- the pairing facilitates rapid evaluation of the transcriptional regulation of each genetic pathway by any NHR in a given context.
- FGF-1 A promoter characterization The expression of the FGF-1 gene is directed by at least three distinct promoters driving the untranslated exons: 1 A, IB, and ID, spaced up to 70 kilobase pairs apart ( Figure 1A) (Myers et al., 1993). Alternative splicing of these untranslated exons to the three coding exons of the FGF-1 gene results in identical but differentially expressed FGF-1 polypeptides.
- FGF-1 A shows the highest expression in heart and kidney but is also expressed in adipose and several other tissues (Figure IB).
- FGF- IB is the only variant expressed in brain, and is also expressed in several other tissues ( Figure 1C).
- FGF- ID is primarily expressed in liver ( Figure ID).
- FGF-1 A PPAR response element
- Figure 2A Inactivation of the PPRE in the FGF-1 A promoter (located at -60 bp relative to the transcription start site (TSS)) by site directed mutagenesis resulted in a complete loss of response of the FGF-1 A promoter to PPARy ( Figure 2F, compare human vs. ⁇ ).
- FGF-1 The gene structure of FGF-1 is highly conserved in a wide range of mammals (e.g., bovine, canine, horse, chimpanzee, orangutan, rat, mouse, and opossum).
- mammals e.g., bovine, canine, horse, chimpanzee, orangutan, rat, mouse, and opossum.
- the PPRE in the FGF-1 A promoter in these species also showed strong conservation (Figure 2D, E).
- FIG. 21 shows the results of quantitative PCR, demonstrating that PPARy specifically binds the FGF1 promoter region.
- 36b4 is a negative control locus that does not include PPARy binding sites.
- FGF-1 is regulated by PPARy in vivo. Short term oral administration of
- rosiglitazone (5 mg/kg for 3 days) or high-fat diet (two weeks) significantly increased the mRNA levels of FGF-1 A in WAT ( Figure 3 A, D).
- This increase was similar to that of the adipocyte protein aP2 (also known as fatty acid binding protein 4, FABP4), which is the strongest known PPARy target in adipose tissue.
- adipocyte protein aP2 also known as fatty acid binding protein 4, FABP4
- overnight fasting resulted in an about two-fold decrease in FGF-1 A mRNA levels.
- levels of FGF-21 were highly induced in the liver by fasting and HFD ( Figure 3B, E) whereas no effects of rosiglitazone or HFD were observed in WAT ( Figure 3C, F).
- rosiglitazone also reduced the expression of FGF-21 in fasted liver (Figure 3B), which is also observed in patients with type 2 diabetes (Li et al, 2009).
- No changes in expression by TZD, HFD, or fasting were observed for FGF-1B and FGF-ID in liver, and for FGF-1B in WAT.
- FGF-1 A and FGF-ID were not detected in liver and WAT, respectively.
- HFD treatment for 3 months in mice also resulted in increased protein levels of FGF-1 (Figure 3G).
- FGF-1 knockout mice FGF-1 knockout mice
- FGF-1 KO mice have been studied in the context of wound healing and cardiovascular changes. Neither these mice, nor FGF-1/FGF2 double KO mice, displayed any significant phenotype under normal feeding conditions (Miller et al., 2000).
- FGF-1 KO and wild-type littermates were fed a high fat diet (HFD).
- HFD high fat diet
- Adiponectin (fast) 12.9 ⁇ 1.2 13.7 ⁇ 1.8 ⁇ g/ml
- Triglycerides (fast) 11.2 ⁇ 1.5 10.2 ⁇ 0.9 mg/dl
- Example 3 AKT signaling is impaired in WAT of HFD-fed FGF-1 KO mice.
- FGFs signal through four cognate high-affinity tyrosine kinase receptors, designated FGFR-1 to -4, leading to downstream activation of multiple signal transduction pathways, including the MAPK (ERK1/2) and PI3K/AKT pathways. These pathways regulate components of the insulin/glucose signaling pathways including activation of glycogen synthase kinase-3 (GSK-3), which regulates glycogen synthesis in response to insulin, and translocation of the glucose transporter GLUT4 (Cho et al., 2001). To investigate the integrity of these signaling pathways, we determined the expression of its critical components in WAT, BAT, liver, and muscle of HFD-fed FGF-1 KO and wild-type mice (Figure 5).
- FGF-1 induces the expression of GLUT1 and acts synergistically with rosiglitazone in 3T3-L1 adipocytes.
- FGF-1 induces the expression of Glucose Transporter 1 (Glutl) in mouse 3T3-L1 adipocytes after prolonged treatment ( Figure 6), and it decreases fed blood glucose in ob/ob mice.
- Glutl Glucose Transporter 1
- Example 5 FGF-1 has hypoglycemic effects in vivo.
- mice Eight-week-old male ob/ob mice were treated with recombinant mouse FGF-1 (0.5 mg/kg/day, s.c. in 250 ⁇ ), rosiglitazone (TZD, 5 mg/kg/day, p.o. in 300 ⁇ ), or vehicle control (s.c. vehicle control 0.9% NaCl, 250 ⁇ /mouse; p.o. vehicle control 0.5 % CMC, 300 ⁇ /mouse). Blood glucose was measured one hour after treatment at day 3 and day 6 using a standard protocol. (Figure 7A).
- FGF-1 is selectively induced in adipose tissue by high-fat diet (HFD) and TZD, and mice lacking FGF-1 develop HFD-induced insulin resistance (IR).
- HFD high-fat diet
- TZD high-fat diet
- IR HFD-induced insulin resistance
- the IR of these mice can be explained by impaired AKT signaling in adipose.
- Administration of FGF-1 to diabetic mice normalizes their glucose levels and improves their fat-lean ratio.
- FGF-1 acts as a powerful insulin sensitizer in adipose tissue and mediates insulin sensitizing actions of TZDs and PPARy.
- Figure 12 shows that FGF-1 administration initially results in reduced food intake of ob/ob mice. Food intake returns to normal within about 2 weeks, but as shown in Figure 13, body weight in FGF-1 treated ob/ob mice remains lower than in untreated ob/ob mice. The reduction in body weight shown in Figure 13 indicates that FGF-1 can be used to produce rapid and durable body weight reduction.
- Figures 14 and 15 compare percent body fat and percent lean mass in FGF-1 treated and untreated ob/ob mice. The results indicate that the reduction in body weight is largely due to reduced percentage body fat. The relative percentage of lean mass in FGF-1 treated mice is significantly higher than in untreated mice ( Figure 15).
- Figure 16 shows the results of a glucose tolerance test carried out after four weeks of FGF-1 administration (0.5mg/kg/3 days, s.c).
- FGF-1 treated ob/ob mice cleared glucose more effectively than untreated controls.
- FGF-1 treated mice also showed increased insulin sensitivity, as indicated by more rapid clearance of glucose in the ITT ( Figure 17).
- Serum lipid levels (triglycerides, free fatty acids, and cholesterol) were similar between the two groups ( Figure 18).
- FIG. 19 shows H&E stained tissue from untreated (A) and treated (B) mice.
- the untreated liver displays significant steatosis (fat deposit and damage), while the liver from FGF-1 treated mice shows much less steatosis, and little if any inflammation.
- liver glycogen levels were much higher in FGF-1 treated mice, which is indicative of proper glucose processing and insulin response (Figure 20).
- Example 11 Multiple delivery methods of FGF-1 are effective for reducing blood glucose
- the ob/ob model is considered to represent a very severe diabetic disease.
- FGF-1 farnesoid growth factor-1
- Figures 24 and 25 show that subcutaneous administration of 0.5 mg/kg FGF-1 was effective for reducing blood glucose levels in both systems. The data indicate that FGF-1 can be used to normalize glucose levels and treat metabolic disorders arising from different causes.
- Example 13 Human recombinant FGF-1 effectively reduces glucose levels in ob/ob mice
- Figure 26 shows that the same dose of hrFGF-1 administered s.c. can effectively reduce glucose levels in ob/ob mice.
- human recombinant FGF-1 is already being used in the clinic, the present methods of using it to treat metabolic disorders offer a straightforward regulatory path to treatment.
- Example 14 Glucose reducing effects are specific to FGF-1
- FGF-1 binds preferentially to FGFR1 and FGFR4, and can be internalized into a cell expressing these receptors.
- FGF-2 binds preferentially to FGFR1 and FGFR4
- FGF-9 binds preferentially to FGFR1 and FGFR4
- FGF-10 0.5 mg/kg s.c. This combination of FGF proteins binds to the spectrum of FGFRs.
- the results shown in Figure 27 demonstrate that the particular receptor binding and signaling properties of FGF-1 are required for the observed metabolic effects.
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2796459A CA2796459C (en) | 2010-04-16 | 2011-04-18 | Methods for treating metabolic disorders using fgf-1 |
US13/641,451 US20130116171A1 (en) | 2010-04-16 | 2011-04-18 | Methods for treating metabolic disorders using fgf |
AU2011239386A AU2011239386B2 (en) | 2010-04-16 | 2011-04-18 | Methods for treating metabolic disorders using FGF |
JP2013505209A JP5767314B2 (en) | 2010-04-16 | 2011-04-18 | Methods for treating metabolic disorders using FGF |
EP11769740.9A EP2558115B1 (en) | 2010-04-16 | 2011-04-18 | Methods for treating metabolic disorders using fgf |
US14/184,621 US8906854B2 (en) | 2010-04-16 | 2014-02-19 | Methods for treating metabolic disorders using FGF |
US14/526,058 US9072708B2 (en) | 2010-04-16 | 2014-10-28 | Methods for treating metabolic disorders using FGF |
US14/731,705 US9446097B2 (en) | 2010-04-16 | 2015-06-05 | Methods for treating metabolic disorders using FGF |
US15/240,803 US9808508B2 (en) | 2010-04-16 | 2016-08-18 | Methods for treating metabolic disorders using FGF |
US15/351,104 US10159711B2 (en) | 2010-04-16 | 2016-11-14 | Methods for treating metabolic disorders using FGF |
US15/703,717 US10398759B2 (en) | 2010-04-16 | 2017-09-13 | Methods for treating metabolic disorders using FGF |
US15/904,614 US10293027B2 (en) | 2010-04-16 | 2018-02-26 | Methods for treating metabolic disorders using FGF |
US16/538,327 US20190358296A1 (en) | 2010-04-16 | 2019-08-12 | Methods for treating metabolic disorders using fgf |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32525510P | 2010-04-16 | 2010-04-16 | |
US32525310P | 2010-04-16 | 2010-04-16 | |
US32526110P | 2010-04-16 | 2010-04-16 | |
US61/325,255 | 2010-04-16 | ||
US61/325,261 | 2010-04-16 | ||
US61/325,253 | 2010-04-16 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/641,451 A-371-Of-International US20130116171A1 (en) | 2010-04-16 | 2011-04-18 | Methods for treating metabolic disorders using fgf |
US14/184,621 Division US8906854B2 (en) | 2010-04-16 | 2014-02-19 | Methods for treating metabolic disorders using FGF |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011130729A2 true WO2011130729A2 (en) | 2011-10-20 |
WO2011130729A3 WO2011130729A3 (en) | 2012-03-29 |
Family
ID=44799376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/032848 WO2011130729A2 (en) | 2010-04-16 | 2011-04-18 | Methods for treating metabolic disorders using fgf |
Country Status (6)
Country | Link |
---|---|
US (9) | US20130116171A1 (en) |
EP (1) | EP2558115B1 (en) |
JP (1) | JP5767314B2 (en) |
AU (1) | AU2011239386B2 (en) |
CA (1) | CA2796459C (en) |
WO (1) | WO2011130729A2 (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014085365A3 (en) * | 2012-11-28 | 2014-08-28 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
US8999929B2 (en) | 2012-06-07 | 2015-04-07 | Salk Institute For Biological Studies | Fibroblast growth factor 1 protein fragments and methods of use |
WO2015061361A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (fgf) 1 and methods of use |
WO2015061351A1 (en) * | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
WO2015061331A1 (en) * | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
US9089525B1 (en) | 2011-07-01 | 2015-07-28 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject |
US9446097B2 (en) | 2010-04-16 | 2016-09-20 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using FGF |
US9464126B2 (en) | 2012-06-07 | 2016-10-11 | New York University | Chimeric fibroblast growth factor 21 proteins and methods of use |
US9475856B2 (en) | 2012-03-02 | 2016-10-25 | New York University | Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders |
WO2016172153A3 (en) * | 2015-04-20 | 2017-01-12 | Salk Institute For Biological Studies | Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose |
US9550820B2 (en) | 2013-02-22 | 2017-01-24 | New York University | Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use |
US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
US20170173114A1 (en) * | 2014-05-07 | 2017-06-22 | Joslin Diabetes Center, Inc. | Methods and compositions for induction of ucp1 expression |
US9878009B2 (en) | 2012-12-27 | 2018-01-30 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having error of bile acid synthesis |
US9925242B2 (en) | 2012-12-27 | 2018-03-27 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis |
US10093735B2 (en) | 2014-01-24 | 2018-10-09 | Ngm Biopharmaceuticals, Inc. | Beta-klotho binding proteins |
EP3368059A4 (en) * | 2015-10-30 | 2019-03-27 | Salk Institute for Biological Studies | Treatment of steroid-induced hyperglycemia with fibroblast growth factor (fgf) 1 analogs |
US10369199B2 (en) | 2013-10-28 | 2019-08-06 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of cancer |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US10517929B2 (en) | 2014-10-23 | 2019-12-31 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising FGF19 variants |
US10744185B2 (en) | 2015-11-09 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of pruritus |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
US11066454B2 (en) | 2012-11-28 | 2021-07-20 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
US11542309B2 (en) | 2019-07-31 | 2023-01-03 | Salk Institute For Biological Studies | Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3071561T (en) | 2013-11-22 | 2021-06-25 | Sabre Therapeutics Llc | Autotaxin inhibitor compounds |
US9051320B1 (en) | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
WO2016130683A1 (en) * | 2015-02-10 | 2016-08-18 | University Of Washington | Prolonged anti-diabetic effect of fibroblast growth factor 1 (fgf1) |
JP6675150B2 (en) * | 2015-04-06 | 2020-04-01 | 公立大学法人大阪 | Cytoglobin expression enhancer |
CA2983268A1 (en) * | 2015-04-20 | 2016-10-27 | Salk Institute For Biological Studies | Fibroblast growth factor (fgf) 1 mutants and methods of use to reduce blood glucose |
EP4026549A1 (en) | 2015-05-27 | 2022-07-13 | Sabre Therapeutics LLC | Autotaxin inhibitors and uses thereof |
WO2020010180A1 (en) * | 2018-07-03 | 2020-01-09 | Cardio Vascular Bio Therapeutics, Inc. | Compositions and methods for treating stroke |
WO2022261480A1 (en) * | 2021-06-11 | 2022-12-15 | The Regents Of The University Of California | Heparan sulfate mimetics to improve glucose clearance |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
WO1991016024A1 (en) | 1990-04-19 | 1991-10-31 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
WO2001075164A2 (en) | 2000-03-30 | 2001-10-11 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
WO2006093814A2 (en) | 2005-02-25 | 2006-09-08 | Biosurface Engineering Technologies, Inc. | Fgf growth factor analogs |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859208A (en) | 1988-07-06 | 1999-01-12 | Fiddes; John C. | Human basic fibroblast growth factor analog |
DE3750197D1 (en) | 1986-04-22 | 1994-08-18 | Salk Inst For Biological Studi | Antagonists of fibroblast growth factor. |
US5656458A (en) | 1988-11-04 | 1997-08-12 | Chiron Corporation | Expression and processing of amino terminus acetylated FGF's in yeast |
US5658889A (en) | 1989-01-24 | 1997-08-19 | Gensia Pharmaceuticals, Inc. | Method and compounds for aica riboside delivery and for lowering blood glucose |
JPH04164096A (en) | 1989-09-29 | 1992-06-09 | Takeda Chem Ind Ltd | Afgf mutein, dna and use thereof |
EP0420222A1 (en) | 1989-09-29 | 1991-04-03 | Takeda Chemical Industries, Ltd. | Mutein of acidic FGF, and its production |
US5478804A (en) | 1990-09-19 | 1995-12-26 | The Salk Institute For Biological Studies | Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates |
DE4132005A1 (en) * | 1991-09-26 | 1993-04-01 | Merck Patent Gmbh | COMBINATION CONTAINING GROWTH FACTORS AND POLYELECTROLYTE |
TW275068B (en) | 1993-09-24 | 1996-05-01 | American Cyanamid Co | |
US5693775A (en) | 1995-05-12 | 1997-12-02 | The Johns Hopkins University School Of Medicine | Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use |
EP0833665A1 (en) | 1995-05-16 | 1998-04-08 | Prizm Pharmaceuticals, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
AU3170499A (en) | 1998-04-28 | 1999-11-16 | Eisai Co. Ltd. | Fibroblast growth factor mutein compositions and methods of use therefor |
US6326484B1 (en) | 1998-05-14 | 2001-12-04 | The Salk Institute For Biological Studies | Nucleic acids encoding regulators of FGF-2 transcription (RFT) and variants thereof |
US6800286B1 (en) | 1998-08-19 | 2004-10-05 | The Regents Of The University Of Colorado | Chimeric fibroblast growth factor proteins, nucleic acid molecules, and uses thereof |
CA2381780C (en) | 1999-08-13 | 2015-03-10 | Chiron Corporation | Dose of an angiogenic factor and method of administering to improve myocardial blood flow |
US7459540B1 (en) * | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US20020115603A1 (en) | 2000-06-22 | 2002-08-22 | Chiron Corporation | Methods and compositions for the treatment of peripheral artery disease |
IL139380A0 (en) | 2000-10-31 | 2001-11-25 | Prochon Biotech Ltd | Active variants of fibroblast growth factor |
WO2002066035A2 (en) | 2001-02-20 | 2002-08-29 | Chugai Seiyaku Kabushiki Kaisha | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
CA2441986A1 (en) | 2001-03-27 | 2002-10-03 | Massachusetts Institute Of Technology | Methods and products related to fgf dimerization |
US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
US6982170B1 (en) * | 2001-12-17 | 2006-01-03 | Maine Medical Center Research Institute | Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1 |
US8142810B2 (en) | 2002-05-30 | 2012-03-27 | The Procter & Gamble Company | Dietary method for modulating glucose metabolism and associated conditions and increasing longevity |
CA2390285A1 (en) | 2002-06-11 | 2003-12-11 | Elissavet Kardami | Non-mitogenic fgf-2 protects against ischemia and/or reperfusion injury |
NZ537208A (en) * | 2002-06-27 | 2009-02-28 | Adipogen Pharmaceuticals Pty Ltd | Differentiation modulating agents and uses therefor |
EP1444995A1 (en) | 2003-02-06 | 2004-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | FGF-2 derived proteins for the preparation of biomaterials or medical devices such as stents |
BRPI0410844A (en) * | 2003-06-05 | 2006-06-27 | Centelion | Plasmid coding fibroblast growth factor for the treatment of angiogenic defects associated with hypercholesterolemia or diabetes |
US7790682B1 (en) | 2003-12-02 | 2010-09-07 | The Florida State University Research Foundation, Inc. | Engineered human acidic fibroblast growth factors and associated methods |
KR20060135648A (en) | 2003-12-10 | 2006-12-29 | 일라이 릴리 앤드 캄파니 | Muteins of fibroblast growth factor 21 |
AU2004309090A1 (en) * | 2003-12-29 | 2005-07-14 | Aventis Pharma Sa | Treatment of coronary or peripheral ischemia |
WO2005072769A1 (en) | 2004-01-26 | 2005-08-11 | Eli Lilly And Company | Use of fgf-21 and thiazolidinedione for treating type 2 diabetes |
CA2557782A1 (en) | 2004-03-17 | 2005-10-06 | Eli Lilly And Company | Glycol linked fgf-21 compounds |
SI1751184T1 (en) | 2004-05-13 | 2010-01-29 | Lilly Co Eli | Fgf-21 fusion proteins |
EP1634877B1 (en) | 2004-08-17 | 2011-06-22 | Simpson Biotech Co., Ltd. | Mixture and compounds from mycelia of antrodia camphorata and use thereof |
DE602005016946D1 (en) | 2004-09-02 | 2009-11-12 | Lilly Co Eli | MUTINES OF FIBROBLAST GROWTH FACTOR 21 |
EP1789443A1 (en) | 2004-09-02 | 2007-05-30 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
WO2006050247A2 (en) * | 2004-10-29 | 2006-05-11 | Neose Technologies, Inc. | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
WO2006065582A2 (en) | 2004-12-14 | 2006-06-22 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
US20080261875A1 (en) | 2005-01-21 | 2008-10-23 | Eli Lilly And Company | Method For Treating Cardiovascular Disease |
US8119358B2 (en) * | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
WO2007081419A2 (en) * | 2005-10-17 | 2007-07-19 | The Regents Of The University Of California | Compositions and methods related to anti-fgf agents |
EP2083846B1 (en) | 2006-09-28 | 2015-07-15 | Hepacore Ltd. | N-terminal fgf variants having increased receptor selectivity and uses thereof |
US20100143330A1 (en) | 2006-10-16 | 2010-06-10 | Unversidadde Salamanca (O.T.R.I.) | Methods of treating disorders associated with fat storage |
US7696171B1 (en) | 2006-11-09 | 2010-04-13 | The Florida State University Research Foundation, Inc. | Mutant polypeptides of fibroblast growth factor 1 |
WO2008092019A1 (en) | 2007-01-25 | 2008-07-31 | Mayo Foundation For Medical Education And Research | Fgf-23 polypeptides |
KR101476472B1 (en) | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | Modified fgf-21 polypeptides and their uses |
AU2008275559B2 (en) | 2007-04-02 | 2014-04-10 | Genentech, Inc. | Klotho-beta for use in treating cancer, liver disorders, gallstones, wasting syndrome and obesity-related diseases |
US8697369B2 (en) | 2007-04-06 | 2014-04-15 | National Institute Of Advanced Industrial Science And Technology | Method for screening a test substance for activating a receptor associated with FGF 21 activity |
US20080260703A1 (en) * | 2007-04-23 | 2008-10-23 | Medistem Labortories | Treatment of Insulin Resistance and Diabetes |
WO2009048119A1 (en) | 2007-10-12 | 2009-04-16 | National Institute Of Advanced Industrial Science And Technology | Medicinal composition containing highly functionalized chimeric protein |
AU2008353145B2 (en) | 2008-01-03 | 2013-09-12 | Universite D' Aix-Marseille | Bitherapy and tritherapy used for treating an HIV-positive patient |
JOP20190083A1 (en) | 2008-06-04 | 2017-06-16 | Amgen Inc | Fgf21 mutant fusion polypeptides and uses thereof |
US7956033B2 (en) | 2008-06-10 | 2011-06-07 | Eu Sol Biotech Co., Ltd. | Modified peptide of human acidic fibroblast growth factor |
WO2010075037A1 (en) | 2008-12-15 | 2010-07-01 | University Of Rochester | Systems and methods for enhancing vaccine efficacy |
US9480753B2 (en) | 2009-01-23 | 2016-11-01 | Novo Nordisk A/S | FGF21 derivatives with albumin binder A-B-C-D-E- and their use |
CN107188950B (en) | 2009-05-05 | 2021-09-28 | 安姆根有限公司 | FGF21 mutant and application thereof |
US20120052069A1 (en) | 2009-05-05 | 2012-03-01 | Amgen Inc | Fgf21 mutants and uses thereof |
US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
CA2764835A1 (en) | 2009-06-17 | 2010-12-23 | Amgen Inc. | Chimeric fgf19 polypeptides and uses thereof |
RU2573896C2 (en) | 2009-10-15 | 2016-01-27 | Дженентек, Инк. | Chimeric fibroblast growth factors with changed receptor specificity |
US8889621B2 (en) | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
US8372952B2 (en) | 2009-12-02 | 2013-02-12 | Amgen Inc. | Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho |
US20110195077A1 (en) | 2010-01-29 | 2011-08-11 | Novartis Ag | Methods and compositions using fgf23 fusion ppolypeptides |
CA2796459C (en) | 2010-04-16 | 2016-05-24 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using fgf-1 |
WO2012010553A1 (en) | 2010-07-20 | 2012-01-26 | Novo Nordisk A/S | N-terminal modified fgf21 compounds |
CN102464712A (en) | 2010-11-11 | 2012-05-23 | 重庆富进生物医药有限公司 | Deletion human fibroblast growth factor 21 variant and conjugate thereof |
US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
US9169309B2 (en) | 2011-03-01 | 2015-10-27 | Humanzyme Inc. | Thermostable variants of fibroblast growth factors |
US8962546B2 (en) | 2011-03-01 | 2015-02-24 | Salk Institute For Biological Studies | Modulation of estrogen receptor-related receptor gamma (ERRγ) and uses therefor |
WO2012140650A2 (en) | 2011-04-12 | 2012-10-18 | Hepacore Ltd. | Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof |
SG10201806648TA (en) | 2011-07-01 | 2018-09-27 | Ngm Biopharmaceuticals Inc | Compositions, uses and methods for treatment of metabolic disorders and diseases |
CA2845357A1 (en) | 2011-08-31 | 2013-03-07 | Amgen Inc. | Method of treating or ameliorating type 1 diabetes using fgf21 |
US8772460B2 (en) | 2011-12-16 | 2014-07-08 | Wisconsin Alumni Research Foundation | Thermostable FGF-2 mutant having enhanced stability |
US9475856B2 (en) | 2012-03-02 | 2016-10-25 | New York University | Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders |
WO2013166153A2 (en) | 2012-05-01 | 2013-11-07 | Brentnall Teri | Methods and compositions for cancer diagnosis |
US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
US9464126B2 (en) | 2012-06-07 | 2016-10-11 | New York University | Chimeric fibroblast growth factor 21 proteins and methods of use |
US9474785B2 (en) | 2012-06-07 | 2016-10-25 | New York University | Chimeric fibroblast growth factor 19 proteins and methods of use |
US20140045751A1 (en) | 2012-08-10 | 2014-02-13 | Florida State University Research Foundation | Recombinant human fibroblast growth factor-1 as a novel therapeutic for ischemic diseases and methods thereof |
US9963494B2 (en) | 2012-11-28 | 2018-05-08 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject |
WO2014130659A1 (en) | 2013-02-22 | 2014-08-28 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
CA2915045A1 (en) | 2013-06-14 | 2014-12-18 | Ottawa Hospital Research Institute | Compositions and methods for enhancing virus replication |
EP3060238A4 (en) | 2013-10-21 | 2017-06-07 | Salk Institute for Biological Studies | Mutated fibroblast growth factor (fgf) 1 and methods of use |
WO2015061331A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
WO2015061351A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
MX2016004822A (en) | 2013-10-28 | 2016-08-17 | Ngm Biopharmaceuticals Inc | Cancer models and associated methods. |
WO2015149069A1 (en) | 2014-03-28 | 2015-10-01 | New York University | Fgf23 fusion proteins |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
WO2015195845A1 (en) | 2014-06-17 | 2015-12-23 | Xycrobe Therapeutics, Inc. | Genetically modified bacteria and methods for genetic modification of bacteria |
WO2015198175A1 (en) | 2014-06-27 | 2015-12-30 | Florida State University Research Foundation, Inc. | Design of fgf-1 mutants to effectively eliminate reactive cysteine residues |
US20180265558A1 (en) | 2014-12-03 | 2018-09-20 | Florida State University Research Foundation, Inc. | Modified fibroblast growth factor 1 (fgf-1) polypeptides with increased binding affinity for heparin and associated methods |
WO2016100820A2 (en) | 2014-12-19 | 2016-06-23 | Salk Institute For Biological Studies | Fgf2 truncations and mutants and uses thereof |
CA2983153A1 (en) | 2015-04-20 | 2016-10-27 | Salk Institute For Biological Studies | Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose |
CA2983268A1 (en) | 2015-04-20 | 2016-10-27 | Salk Institute For Biological Studies | Fibroblast growth factor (fgf) 1 mutants and methods of use to reduce blood glucose |
WO2016172290A1 (en) | 2015-04-21 | 2016-10-27 | Salk Institute For Biological Studies | Methods of treating lipodystrophy using fgf-1 compounds |
CA3002400A1 (en) | 2015-10-30 | 2017-05-04 | Salk Institute For Biological Studies | Treatment of steroid-induced hyperglycemia with fibroblast growth factor (fgf) 1 analogs |
WO2018018010A1 (en) | 2016-07-21 | 2018-01-25 | Metacrine, Inc. | Fgf mutants and uses thereof |
WO2018026713A1 (en) | 2016-08-01 | 2018-02-08 | Salk Institute For Biological Studies | Fibroblast growth factor (fgf) 1 proteins with glucose lowering ability and reduced mitogenicity |
-
2011
- 2011-04-18 CA CA2796459A patent/CA2796459C/en active Active
- 2011-04-18 JP JP2013505209A patent/JP5767314B2/en active Active
- 2011-04-18 WO PCT/US2011/032848 patent/WO2011130729A2/en active Application Filing
- 2011-04-18 EP EP11769740.9A patent/EP2558115B1/en active Active
- 2011-04-18 US US13/641,451 patent/US20130116171A1/en not_active Abandoned
- 2011-04-18 AU AU2011239386A patent/AU2011239386B2/en active Active
-
2014
- 2014-02-19 US US14/184,621 patent/US8906854B2/en active Active
- 2014-10-28 US US14/526,058 patent/US9072708B2/en active Active
-
2015
- 2015-06-05 US US14/731,705 patent/US9446097B2/en active Active
-
2016
- 2016-08-18 US US15/240,803 patent/US9808508B2/en active Active
- 2016-11-14 US US15/351,104 patent/US10159711B2/en active Active
-
2017
- 2017-09-13 US US15/703,717 patent/US10398759B2/en active Active
-
2018
- 2018-02-26 US US15/904,614 patent/US10293027B2/en active Active
-
2019
- 2019-08-12 US US16/538,327 patent/US20190358296A1/en not_active Abandoned
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
WO1991016024A1 (en) | 1990-04-19 | 1991-10-31 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
WO2001075164A2 (en) | 2000-03-30 | 2001-10-11 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
WO2006093814A2 (en) | 2005-02-25 | 2006-09-08 | Biosurface Engineering Technologies, Inc. | Fgf growth factor analogs |
Non-Patent Citations (71)
Title |
---|
"Basic and Clinical Pharmacology", 21 September 2000, MCGRAW-HILL/APPLETON & LANGE |
"Current Protocols in Molecular Biology", 2007 |
"Fundamental Immunology", 1993 |
"Goodman and Gilman's The Pharmacological Basis of Therapeutics", 2001, MCGRAW HILL, article "United States Pharmacopeia (U.S.P." |
"Methods in Enzymology", vol. 182, 1990, article "Guide to Protein Purification" |
"Molecular Cloning: A Laboratory Manual", 2001 |
"Physician's Desk Reference", THOMSON PUBLISHING |
"The Merck Manual of Diagnosis and Therapy", 2006, MERCK PUBLISHING GROUP |
"The Merck Veterinary Manual", 2005, MERCK PUBLISHING GROUP |
ABELSON ET AL.: "Methods in Enzymology", vol. 289, 1997, article "Solid-Phase Peptide Synthesis" |
AHMAD ET AL., CANCER RES., vol. 52, 1992, pages 4817 - 4820 |
AMOS ET AL., DIABETIC MED., vol. 14, 1997, pages 1 - 85 |
ANDERSON, SCIENCE, vol. 256, 1992, pages 808 - 813 |
ARONOFF ET AL., DIABETES CARE, vol. 23, 2000, pages 1605 - 1611 |
BAIRD ET AL., CANCER CELLS, vol. 3, 1991, pages 239 - 243 |
BASS, NATURE, vol. 411, 2001, pages 428 - 29 |
BEHR ET AL., BIOCONJUGATE CHEM., vol. 5, 1994, pages 382 - 389 |
BLAESE ET AL., CANCER GENE THER., vol. 2, 1995, pages 291 - 297 |
CLARK-CURTISS; CURTISS ET AL.: "Methods in Enzymology", vol. 101, 1983, pages: 347 - 362 |
COLLEY ET AL., J. BIOL. CHEM., vol. 264, 1989, pages 17619 - 17622 |
CREIGHTON, PROTEINS, 1984 |
CRYSTAL, SCIENCE, vol. 270, 1995, pages 404 - 410 |
DAY, DIABET MED, vol. 16, 1999, pages 179 - 192 |
DEUTSCHER, METHODS IN ENZYMOLOGY, vol. 182, 1990, pages 83 - 9 |
DILLON, TIBTECH, vol. 11, 1993, pages 167 - 175 |
ELBAHIR ET AL., NATURE, vol. 411, 2001, pages 494 - 98 |
FIRE ET AL., NATURE, vol. 391, 1998, pages 806 - 11 |
GAO ET AL., GENE THERAPY, vol. 2, 1995, pages 710 - 722 |
GOTTSCHLING ET AL., DIABETOLOGIA, vol. 43, 2000, pages 377 - 383 |
HADDADA ET AL., CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, 1995 |
HAUNER, DIABETES METAB RES REV, vol. 18, 2002, pages S10 - S15 |
HUNTLEY ET AL., DIABETES, vol. 53, no. 12, 2004, pages 3097 - 3106 |
INCHOVSKA ET AL., ACTA MORPHOLOGICA ET ANTHROPOLOGICA, vol. 12, 2007, pages 79 - 85 |
INCHOVSKA ET AL., ARCHIVES OF MEDICAL SCIENCE, vol. 2, no. 2, 2006, pages 90 - 93 |
INCHOVSKA ET AL., CELL PROLIFERATION, vol. 39, no. 6, 2006, pages 537 - 550 |
KREMER; PERRICAUDET, BRITISH MEDICAL BULLETIN, vol. 51, no. 1, 1995, pages 31 - 44 |
LEBOVITZ ET AL., J CLIN ENDOCRINOL METAB, vol. 86, 2001, pages 280 - 288 |
LUI ET AL., CANCER RES., vol. 67, 2007, pages 2712 |
MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554 |
MCKEEHAN ET AL., PROG. NUCLEIC ACID RES. MOL. BIOL., vol. 59, 1998, pages 135 - 176 |
MERRIFIELD, J. AM. CHEM. SOC., vol. 85, 1963, pages 2149 - 2154 |
MILLER, NATURE, vol. 357, 1992, pages 455 - 460 |
MITANI; CASKEY, TIBTECH, vol. 11, 1993, pages 162 - 166 |
MOLLER, NATURE, vol. 414, 2001, pages 821 - 827 |
MORRISON, J. BACT., vol. 132, 1977, pages 349 - 351 |
MOSBACH ET AL., NATURE, vol. 302, 1983, pages 543 - 545 |
NABEL; FEIGNER, TIBTECH, vol. 11, 1993, pages 211 - 217 |
NIKOL ET AL., MOL THER., 2008 |
OAKES ET AL., DIABETES, vol. 43, 1994, pages 1203 - 1210 |
OAKES ET AL., METABOLISM, vol. 46, 1997, pages 935 - 942 |
OGIHARA ET AL., AM J HYPERTENS, vol. 8, 1995, pages 316 - 320 |
OGNEVA ET AL., DIABETES RESEARCH AND CLINICAL PRACTICE, vol. 57, no. 1, 2002, pages 11 - 16 |
PALVA ET AL., GENE, vol. 22, 1983, pages 229 - 235 |
PAUL, FUNDAMENTAL IMMUNOLOGY, 2003 |
PHILLIPS ET AL., DIABETES CARE, vol. 24, 2001, pages 308 - 315 |
REMY ET AL., BIOCONJUGATE CHEM., vol. 5, 1994, pages 647 - 654 |
REUSS ET AL., CELL TISSUE RES., vol. 313, 2003, pages 139 - 157 |
SAMBROOK ET AL.: "MOLECULAR CLONING, A LABORATORY MANUAL", 1989, COLD SPRINGS HARBOR PRESS |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
SCHEEN ET AL., DIABETES CARE, vol. 22, no. 9, 1999, pages 1568 - 1577 |
SCOPES: "Protein Purification: Principles and Practice", 1982, SPRINGER-VERLAG |
See also references of EP2558115A4 |
SHI ET AL., IUBMB LIFE, vol. 63, 2011, pages 129 |
SINGLETON ET AL.: "DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY", 1994, J. WILEY & SONS |
SMITH ET AL., DIABETES OBES METAB, vol. 2, 2000, pages 363 - 372 |
SORENSEN ET AL., J CELL SCIENCE, vol. 119, 2006, pages 4332 |
VAN BRUNT, BIOTECHNOLOGY, vol. 6, no. 10, 1988, pages 1149 - 1154 |
VIGNE, RESTORATIVE NEUROLOGY AND NEUROSCIENCE, vol. 8, 1995, pages 35 - 36 |
WIDBERG ET AL., AMERICAN JOURNAL OF PHYSIOLOGY: ENDOCRINOLOGY AND METABOLISM, vol. 296, 2009, pages 121 - 131 |
YOUNG ET AL., DIABETES, vol. 44, 1995, pages 1087 - 1092 |
YU ET AL., GENE THERAPY, vol. 1, 1994, pages 13 - 26 |
Cited By (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10398759B2 (en) | 2010-04-16 | 2019-09-03 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using FGF |
US10293027B2 (en) | 2010-04-16 | 2019-05-21 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using FGF |
US9446097B2 (en) | 2010-04-16 | 2016-09-20 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using FGF |
US10159711B2 (en) | 2010-04-16 | 2018-12-25 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using FGF |
US9808508B2 (en) | 2010-04-16 | 2017-11-07 | Salk Institude for Biological Studies | Methods for treating metabolic disorders using FGF |
US9670260B2 (en) | 2011-07-01 | 2017-06-06 | Ngm Biopharmaceuticals, Inc. | Compositions comprising fusion variants of FGF19 polypeptides |
US11065302B2 (en) | 2011-07-01 | 2021-07-20 | Ngm Biopharmaceuticals, Inc. | Compositions comprising fusion variants of FGF19 polypeptides |
US10413590B2 (en) | 2011-07-01 | 2019-09-17 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subject |
US9089525B1 (en) | 2011-07-01 | 2015-07-28 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject |
US9751924B2 (en) | 2011-07-01 | 2017-09-05 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising fusion variants of FGF19 polypeptides for reducing glucose levels in a subject |
US10174090B2 (en) | 2012-03-02 | 2019-01-08 | New York University | FGF21 protein with enhanced binding affinity for β-Klotho for the treatment of type II diabetes, obesity, and related metabolic disorders |
US9475856B2 (en) | 2012-03-02 | 2016-10-25 | New York University | Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders |
US10703788B2 (en) | 2012-06-07 | 2020-07-07 | New York University | Chimeric fibroblast growth factor 21 proteins and methods of use |
US9926355B2 (en) | 2012-06-07 | 2018-03-27 | New York University | Chimeric fibroblast growth factor 21 proteins and methods of use |
US8999929B2 (en) | 2012-06-07 | 2015-04-07 | Salk Institute For Biological Studies | Fibroblast growth factor 1 protein fragments and methods of use |
US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
US10633424B2 (en) | 2012-06-07 | 2020-04-28 | New York University | Chimeric fibroblast growth factor 19 proteins and methods of use |
US9474785B2 (en) | 2012-06-07 | 2016-10-25 | New York University | Chimeric fibroblast growth factor 19 proteins and methods of use |
US10364278B2 (en) | 2012-06-07 | 2019-07-30 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
US9464126B2 (en) | 2012-06-07 | 2016-10-11 | New York University | Chimeric fibroblast growth factor 21 proteins and methods of use |
US9926356B2 (en) | 2012-06-07 | 2018-03-27 | New York University | Chimeric fibroblast growth factor 19 proteins and methods of use |
US10758590B2 (en) | 2012-11-28 | 2020-09-01 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF 19 polypeptides for treating diabetes |
US11066454B2 (en) | 2012-11-28 | 2021-07-20 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
WO2014085365A3 (en) * | 2012-11-28 | 2014-08-28 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
US9963494B2 (en) | 2012-11-28 | 2018-05-08 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject |
US9889178B2 (en) | 2012-12-27 | 2018-02-13 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having nonalcoholic steatohepatitis |
US11103554B2 (en) | 2012-12-27 | 2021-08-31 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants of FGF19 polypeptides for reducing bile acid synthesis in a subject having cirrhosis |
US9889177B2 (en) | 2012-12-27 | 2018-02-13 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having primary sclerosing cholangitis |
US11564972B2 (en) | 2012-12-27 | 2023-01-31 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants of FGF19 polypeptides for treating primary biliary cirrhosis in a subject |
US9974833B2 (en) | 2012-12-27 | 2018-05-22 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having pregnancy intrahepatic cholestasis |
US9878009B2 (en) | 2012-12-27 | 2018-01-30 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having error of bile acid synthesis |
US9878008B2 (en) | 2012-12-27 | 2018-01-30 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having bile acid diarrhea or bile acid malabsorption |
US9925242B2 (en) | 2012-12-27 | 2018-03-27 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis |
US9895416B2 (en) | 2012-12-27 | 2018-02-20 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having cholestasis |
US9550820B2 (en) | 2013-02-22 | 2017-01-24 | New York University | Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use |
WO2015061361A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (fgf) 1 and methods of use |
WO2015061331A1 (en) * | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
US9925243B2 (en) | 2013-10-21 | 2018-03-27 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (FGF) 2/FGF1 peptides and methods of use |
CN105828833A (en) * | 2013-10-21 | 2016-08-03 | 萨克生物研究学院 | Mutated fibroblast growth factor (fgf) 1 and methods of use |
WO2015061351A1 (en) * | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
AU2014340241B2 (en) * | 2013-10-21 | 2018-11-01 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (FGF) 1 and methods of use |
US9925241B2 (en) | 2013-10-21 | 2018-03-27 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (FGF) 1 and methods of use |
US10369199B2 (en) | 2013-10-28 | 2019-08-06 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of cancer |
US11596676B2 (en) | 2014-01-24 | 2023-03-07 | Ngm Biopharmaceuticals, Inc. | Methods of treating nonalcoholic steatohepatitis comprising administering an anti-human beta klotho antibody or binding fragment thereof |
US10744191B2 (en) | 2014-01-24 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins and methods of use thereof |
US10093735B2 (en) | 2014-01-24 | 2018-10-09 | Ngm Biopharmaceuticals, Inc. | Beta-klotho binding proteins |
US20170173114A1 (en) * | 2014-05-07 | 2017-06-22 | Joslin Diabetes Center, Inc. | Methods and compositions for induction of ucp1 expression |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US11241481B2 (en) | 2014-06-16 | 2022-02-08 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US10517929B2 (en) | 2014-10-23 | 2019-12-31 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising FGF19 variants |
US11141460B2 (en) | 2014-11-07 | 2021-10-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
WO2016172153A3 (en) * | 2015-04-20 | 2017-01-12 | Salk Institute For Biological Studies | Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
US11667708B2 (en) | 2015-07-29 | 2023-06-06 | Ngm Biopharmaceuticals, Inc. | Anti-human beta klotho antibody or binding fragment thereof and methods of their use |
US10695404B2 (en) | 2015-10-30 | 2020-06-30 | Salk Institute For Biological Studies | Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs |
EP3368059A4 (en) * | 2015-10-30 | 2019-03-27 | Salk Institute for Biological Studies | Treatment of steroid-induced hyperglycemia with fibroblast growth factor (fgf) 1 analogs |
US10744185B2 (en) | 2015-11-09 | 2020-08-18 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of pruritus |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
US11542309B2 (en) | 2019-07-31 | 2023-01-03 | Salk Institute For Biological Studies | Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose |
Also Published As
Publication number | Publication date |
---|---|
US20170056475A1 (en) | 2017-03-02 |
AU2011239386B2 (en) | 2015-03-19 |
US20150065419A1 (en) | 2015-03-05 |
US20190358296A1 (en) | 2019-11-28 |
US9808508B2 (en) | 2017-11-07 |
CA2796459A1 (en) | 2011-10-20 |
AU2011239386A1 (en) | 2012-12-06 |
EP2558115B1 (en) | 2019-07-31 |
JP5767314B2 (en) | 2015-08-19 |
US20140171361A1 (en) | 2014-06-19 |
US9072708B2 (en) | 2015-07-07 |
EP2558115A2 (en) | 2013-02-20 |
WO2011130729A3 (en) | 2012-03-29 |
US20150343022A1 (en) | 2015-12-03 |
US20180036377A1 (en) | 2018-02-08 |
US8906854B2 (en) | 2014-12-09 |
JP2013525309A (en) | 2013-06-20 |
EP2558115A4 (en) | 2014-01-08 |
US20160354440A1 (en) | 2016-12-08 |
US10398759B2 (en) | 2019-09-03 |
US20180200334A1 (en) | 2018-07-19 |
CA2796459C (en) | 2016-05-24 |
US9446097B2 (en) | 2016-09-20 |
US10293027B2 (en) | 2019-05-21 |
US10159711B2 (en) | 2018-12-25 |
US20130116171A1 (en) | 2013-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10293027B2 (en) | Methods for treating metabolic disorders using FGF | |
US20200095585A1 (en) | Methods for Producing Enteroendocrine Cells That Make and Secrete Insulin | |
US9789160B2 (en) | Treatments for lowering glucose levels using FGF binding protein 3 | |
US10426818B2 (en) | Method and pharmaceutical composition for use in the treatment of diabetes | |
WO2020228360A1 (en) | Fusion protein for treatment of metabolic disease | |
JP5847590B2 (en) | Biomaterials and their use | |
WO2008134632A1 (en) | Wnt ligands involved in blood-brain barrier development and uses therefor | |
KR20130132723A (en) | Methods of treatment | |
US20150361146A1 (en) | MG53 Mutant, Methods of Mutation and Use Thereof | |
Aaldijk et al. | Biological and pharmacological functions of the FGF19-and FGF21-coreceptor beta klotho | |
CA2906982C (en) | Methods for treatment of nephrotic syndrome and related conditions | |
KR102240763B1 (en) | Use of TAZ to control blood sugar by controlling PDX1 activity | |
KR102262663B1 (en) | Composition for preventing or treating neurodegenerative diseases comprising IFT88 inhibitor as an active ingredient | |
WO2023246928A1 (en) | Fusion protein containing improved glp-1 receptor agonist and uses | |
CN111944035A (en) | FGF4 and application thereof | |
WO2023010049A1 (en) | Therapeutic uses of isthmin protein | |
CN117959442A (en) | Agent for preventing or treating pulmonary fibrosis and application thereof | |
JP2023511245A (en) | Inhibition of VE-PTP phosphatase protects the kidney from ischemia-reperfusion injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11769740 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2796459 Country of ref document: CA Ref document number: 2013505209 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011769740 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2011239386 Country of ref document: AU Date of ref document: 20110418 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13641451 Country of ref document: US |